Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 21

What was the date of diagnosis?1 __ __ __ __ - __ __- __ __

Was documentation submitted to the CIBMTR? (e.g. pathology report used for diagnosis)

Yes No

2

Did a histologic transformation occur at any time after CLL diagnosis?

yes no

3

Date of transformation:4 __ __ __ __ - __ __- __ __

Specify the disease classification after transformation5

Diffuse large B-cell lymphoma (Richter syndrome) Also complete CIBMTR form 2018 - LYM

Other disease classification

Specify other disease classification:6

Was documentation submitted to the CIBMTR? (e.g. pathology report at transformation)

Yes No

7

Immune hemolytic anemia

Yes No Unknown

8

Immune thrombocytopenia

Yes No Unknown

9

Other

Yes No Unknown

10

Specify other autoimmune disorder:11

Rai stage (at diagnosis)

Known Unknown

12

What was the Rai stage? (at diagnosis)13

Stage 0 - Low risk - lymphocytosis (> 15,000 x 109/L) in blood or bone marrow only without lymphadenopathy, hepatosplenomegaly, anemia or thrombocytopenia

Stage I - Intermediate risk - lymphocytosis plus enlarged lymph nodes (lymphadenopathy) without hepatosplenomegaly, anemia or thrombocytopenia

Stage II - Intermediate risk - lymphocytosis plus enlarged liver or spleen with or without lymphadenopathy

Stage III - High risk - lymphocytosis plus anemia (Hgb < 11.0 g/dL) with or without enlarged liver, spleen, or lymph nodes

Stage IV - High risk - lymphocytosis plus thrombocytopenia (platelet count < 100 x 109/L) with or without anemia or enlarged liver, spleen, or lymph nodes

Binet stage (at diagnosis)

Known Unknown

14

What was the Binet stage? (at diagnosis) (Five lymphoid bearing areas are possible: axillary, cervical, inguino-femoral, liver, and spleen.)15

Stage A - two or fewer lymphoid bearing areas enlarged, without anemia or thrombocytopenia

Stage B - three or more lymphoid bearing areas enlarged, without anemia or thrombocytopenia

Stage C - presence of anemia (Hgb < 10.0 g/dL) or thrombocytopenia (platelet count < 100 x 109/L)

Were systemic symptoms (B symptoms) present? (unexplained fever > 38° C; or night sweats; unexplained weight loss > 10% of body weight in six months before diagnosis)

yes no Unknown

16

Was extranodal disease present?

Yes No

17

Central nervous system (CNS)

Yes No

18

Lung

yes no

19

Other site

yes no

20

Specify other site:21

Laboratory Studies at Diagnosis Questions: 22 - 73

WBC

Known Unknown

22

23 x 109/L (x 103/mm3)

x 106/L

Hemoglobin (untransfused)

Known Unknown

24

25 g/dL g/L mmol/L

Platelets (untransfused)

Known Unknown

26

27 x 109/L (x 103/mm3)

x 106/L

Lymphocytes

Known Unknown

28

29 %

Prolymphocytes

Known Unknown

30

31 %

LDH

Known Unknown

32

33 U/L µkat/L

Upper limit of normal for LDH:34 U/L µkat/L

Serum β2 microglobulin

Known Unknown

35

36 μg/dL mg/L nmol/L

Upper limit of normal for serum ß2 microglobulin:37 μg/dL mg/L nmol/L

Lymphocytes in bone marrow

Known Unknown

38

39 %

Leukemia cell type (may be determined at any time after diagnosis)

B-cell T-cell Unknown

40

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

41

Date sample collected:42 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

43

Specify method used44

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:45

NOTCH 1 mutation

Positive Negative Not done

46

P53 mutation

Positive Negative Not done

47

SF3B1 mutation

Positive Negative Not done

48

Other molecular marker

Positive Negative Not Done

49

Specify other molecular marker:50

Was documentation submitted to the CIBMTR?

Yes No

51

Was flow cytometry (immunophenotyping) performed?

yes no Unknown

52

CD5+

Positive Negative Not Done

53

CD19+

Positive Negative Not Done

54

CD20+

Positive Negative Not Done

55

CD23+

Positive Negative Not Done

56

CD38+

Positive Negative Not done

57

Specify percent positivity

≥30% positivity <30% positivity

58

SIg

Positive Negative Not done

59

ZAP-70 - mutated

Positive Negative Not done

60

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

61

Results of tests62

Abnormalities identified

No evaluable metaphases

No abnormalities

+12

Yes No

63

t(11;14)

yes no

64

Any other translocation of 14

Yes No

65

del(11q) / 11q–

yes no

66

del(13q) / 13q-

yes no

67

del (17p) / 17p-

yes no

68

Chromosome 6 abnormalities

Yes No

69

Chromosome 8 abnormalities

Yes No

70

Other abnormality

yes no

71

Specify other abnormality:72

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

73

Pre-HCT or Pre-Infusion Therapy Questions: 74 - 148

Was therapy given?

yes no Unknown

74

Line of Therapy (1) Questions: 75 - 148

Systemic therapy

yes no

75

Date therapy started

Known Unknown

76

Date started:77 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

78

Date stopped:79 __ __ __ __ - __ __- __ __

Number of cycles

Known Unknown

80

Number of cycles:81

Alemtuzumab (Campath)

yes no

82

Bendamustine

yes no

83

Chlorambucil (Leukeran)

yes no

84

Cladribine (2-CdA, Leustatin)

yes no

85

Corticosteroids

yes no

86

Cyclophosphamide (Cytoxan)

yes no

87

Cytarabine (Ara-C)

yes no

88

Doxorubicin (Adriamycin)

yes no

89

Etoposide (VP-16, VePesid)

yes no

90

Fludarabine (Fludara)

yes no

91

Gemcitabine (Gemzar)

yes no

92

Ibrutinib (Imbruvica)

Yes No

93

Idelalisib (Zydelig)

Yes No

94

Ifosfamide (Ifex)

yes no

95

Lenalidomide (Revlimid)

yes no

96

Nelarabine

Yes No

97

Nitrogen mustard (mustine)

yes no

98

Obinutuzumab

Yes No

99

Oblimersen

Yes No

100

Ofatumumab (Arzerra, HuMAX-CD20)

yes no

101

Pentostatin (Nipent)

yes no

102

Rituximab (anti-CD20, Rituxan)

yes no

103

Venetoclax

Yes No

104

Vincristine (VCR, Oncovin)

yes no

105

Other systemic therapy

yes no

106

Specify other systemic therapy:107

Was this line of therapy given for stem cell mobilization (priming)?

yes no

108

Radiation therapy

yes no

109

Date therapy started

Known Unknown

110

Date started:111 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

112

Date stopped:113 __ __ __ __ - __ __- __ __

Mediastinum

Yes No

114

Other site

yes no

115

Specify other site:116

Surgery

yes no

117

Date of surgery:118 __ __ __ __ - __ __- __ __

Splenectomy

yes no

119

Other site

yes no

120

Specify other site:121

Best response to line of therapy122

Complete
remission (CR)

­ no lymphadenopathy; no organomegaly; neutrophils ≥ 1.5 x 109/L; platelets > 100 x 109/L; hemoglobin > 11.0 g/dL; lymphocytes < 4 x 109/L;
bone marrow < 30% lymphocytes; absence of constitutional symptoms

Partial
remission
(PR)

- ≥ 50% decrease in peripheral blood lymphocyte count from pretreatment value; ≥ 50% reduction in lymphadenopathy if present pretreatment; ≥ 50%
reduction in liver and spleen size if enlarged pretreatment; one or more of the following: neutrophils ≥ 1.5 x 109/L or 50% improvement over baseline,
platelets > 100 x 109/L or 50% improvement over baseline, hemoglobin > 11.0 g/dL or 50% improvement over baseline

Stable disease (SD) - no change; not complete remission, partial remission, nor progressive disease

Progressive
disease
(Prog)

­ one or more of the following: ≥ 50% increase in the sum of the products of ≥ 2 lymph nodes (≥ 1 node must be ≥ 2 cm) or new nodes; ≥ 50%
increase in liver or spleen size, or new hepatomegaly or splenomegaly; ≥ 50% increase in absolute lymphocyte count to ≥ 5 x 109/L; transformation to
a more aggressive histology

Not assessed

Unknown

Date assessed:123 __ __ __ __ - __ __- __ __

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

124

Date sample collected:125 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

126

Specify method used127

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:128

NOTCH 1 mutation

Positive Negative Not done

129

P53 mutation

Positive Negative Not done

130

SF3B1 mutation

Positive Negative Not done

131

Other molecular marker

Positive Negative Not Done

132

Specify other molecular marker:133

Was the disease status assessed via flow cytometry? (minimum 4-color flow) (immunophenotyping)

yes no

134

Date sample collected:135 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

136

Was the disease status assessed by cytogenetic testing (karyotyping or FISH)?

yes no

137

Was the disease status assessed via FISH?

yes no

138

Date sample collected:139 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

140

Was the disease status assessed via karyotyping?

Yes No

141

Date sample collected:142 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

143

Was the disease status assessed by clinical / hematologic assessment?

yes no

144

Date assessed:145 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

146

Did disease relapse/progress following this line of therapy?

yes no

147

Date of relapse/progression:148 __ __ __ __ - __ __- __ __

Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 149 - 191

Did the recipient have known nodal involvement?

yes no

149

Specify the size of the largest nodal mass:150 cm x cm

Was extranodal disease present?

Yes No

151

Central nervous system (CNS)

Yes No

152

Lung

yes no

153

Other site

yes no

154

Specify other site:155

Prolymphocytes

Known Unknown

156

157 %

Serum β2 microglobulin

Known Unknown

158

159 μg/dL mg/L nmol/L

Upper limit of normal for serum ß2 microglobulin:160 μg/dL mg/L nmol/L

Lymphocytes in bone marrow

Known Unknown

161

162 %

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

163

Date sample collected:164 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

165

Specify method used166

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:167

NOTCH 1 mutation

Positive Negative Not done

168

P53 mutation

Positive Negative Not done

169

SF3B1 mutation

Positive Negative Not done

170

Other molecular marker

Positive Negative Not Done

171

Specify other molecular marker:172

Was documentation submitted to the CIBMTR?

Yes No

173

Was the disease status assessed via flow cytometry? (minimum 4-color flow) (immunophenotyping)

yes no

174

Date sample collected:175 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

176

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

177

Results of tests178

Abnormalities identified

No evaluable metaphases

No abnormalities

+12

Yes No

179

t(11;14)

yes no

180

Any other translocation of 14

Yes No

181

del(11q) / 11q–

yes no

182

del(13q) / 13q-

yes no

183

del (17p) / 17p-

yes no

184

Chromosome 6 abnormalities

Yes No

185

Chromosome 8 abnormalities

Yes No

186

Other abnormality

yes no

187

Specify other abnormality:188

Was the disease status assessed by clinical / hematologic assessment?

yes no

189

Date assessed:190 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

191

Disease Status at the Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 192 - 193

What was the disease status?192

Complete
remission (CR)

­ no lymphadenopathy; no organomegaly; neutrophils ≥ 1.5 x 109/L; platelets > 100 x 109/L; hemoglobin > 11.0 g/dL; lymphocytes < 4 x 109/L; bone
marrow < 30% lymphocytes; absence of constitutional symptoms

Partial
remission
(PR)

­ ≥ 50% decrease in peripheral blood lymphocyte count from pretreatment value; ≥ 50% reduction in lymphadenopathy if present pretreatment; ≥ 50% reduction
in liver and spleen size if enlarged pretreatment; one or more of the following: neutrophils ≥ 1.5 x 109/L or 50% improvement over baseline, platelets > 100 x
109/L or 50% improvement over baseline, hemoglobin > 11.0 g/dL or 50% improvement over baseline

Stable disease (SD) - no change; not complete remission, partial remission, nor progressive disease

Progressive
disease
(Prog)

­ one or more of the following: ≥ 50% increase in the sum of the products of ≥ 2 lymph nodes (≥ 1 node must be ≥ 2 cm) or new nodes; ≥ 50% increase in
liver or spleen size, or new hepatomegaly or splenomegaly; ≥ 50% increase in absolute lymphocyte count to ≥ 5 x 109/L; transformation to a more aggressive
histology

Untreated - no chemotherapy given in the 6 months prior to HCT

Not assessed

Date assessed:193 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

If this is a report of a second or subsequent transplant or cellular therapy for the same disease subtype and this baseline disease insert has not been completed for the previous
transplant or cellular therapy (e.g. patient was on TED track for the prior HCT, prior HCT was autologous with no consent, prior cellular therapy was not reported to the CIBMTR),
begin the form at question one.

If this is a report of a second or subsequent transplant or cellular therapy for a different disease, begin the form at question one.

Autoimmune disorder(s) at diagnosis:

Specify site(s) of disease:

Immunophenotype: (may be determined at any time after diagnosis)

Specify cytogenetic abnormalities identified at diagnosis:

Trisomy

Translocation

Deletion

Other

Specify site(s) of radiation therapy:

Specify site(s) of involvement:

Specify cytogenetic abnormalities detected at last evaluation prior to the start of the preparative regimen / infusion:

Trisomy

Translocation

Deletion

Other

Center: CRID: 

Form 2013 R3.0: Chronic Lymphocytic Leukemia (CLL) Pre-Infusion Data

CIBMTR Form 2013 revision 3.0 last updated Wednesday, November 16, 2016
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 1 / 8



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 21

What was the date of diagnosis?1 __ __ __ __ - __ __- __ __

Was documentation submitted to the CIBMTR? (e.g. pathology report used for diagnosis)

Yes No

2

Did a histologic transformation occur at any time after CLL diagnosis?

yes no

3

Date of transformation:4 __ __ __ __ - __ __- __ __

Specify the disease classification after transformation5

Diffuse large B-cell lymphoma (Richter syndrome) Also complete CIBMTR form 2018 - LYM

Other disease classification

Specify other disease classification:6

Was documentation submitted to the CIBMTR? (e.g. pathology report at transformation)

Yes No

7

Immune hemolytic anemia

Yes No Unknown

8

Immune thrombocytopenia

Yes No Unknown

9

Other

Yes No Unknown

10

Specify other autoimmune disorder:11

Rai stage (at diagnosis)

Known Unknown

12

What was the Rai stage? (at diagnosis)13

Stage 0 - Low risk - lymphocytosis (> 15,000 x 109/L) in blood or bone marrow only without lymphadenopathy, hepatosplenomegaly, anemia or thrombocytopenia

Stage I - Intermediate risk - lymphocytosis plus enlarged lymph nodes (lymphadenopathy) without hepatosplenomegaly, anemia or thrombocytopenia

Stage II - Intermediate risk - lymphocytosis plus enlarged liver or spleen with or without lymphadenopathy

Stage III - High risk - lymphocytosis plus anemia (Hgb < 11.0 g/dL) with or without enlarged liver, spleen, or lymph nodes

Stage IV - High risk - lymphocytosis plus thrombocytopenia (platelet count < 100 x 109/L) with or without anemia or enlarged liver, spleen, or lymph nodes

Binet stage (at diagnosis)

Known Unknown

14

What was the Binet stage? (at diagnosis) (Five lymphoid bearing areas are possible: axillary, cervical, inguino-femoral, liver, and spleen.)15

Stage A - two or fewer lymphoid bearing areas enlarged, without anemia or thrombocytopenia

Stage B - three or more lymphoid bearing areas enlarged, without anemia or thrombocytopenia

Stage C - presence of anemia (Hgb < 10.0 g/dL) or thrombocytopenia (platelet count < 100 x 109/L)

Were systemic symptoms (B symptoms) present? (unexplained fever > 38° C; or night sweats; unexplained weight loss > 10% of body weight in six months before diagnosis)

yes no Unknown

16

Was extranodal disease present?

Yes No

17

Central nervous system (CNS)

Yes No

18

Lung

yes no

19

Other site

yes no

20

Specify other site:21

Laboratory Studies at Diagnosis Questions: 22 - 73

WBC

Known Unknown

22

23 x 109/L (x 103/mm3)

x 106/L

Hemoglobin (untransfused)

Known Unknown

24

25 g/dL g/L mmol/L

Platelets (untransfused)

Known Unknown

26

27 x 109/L (x 103/mm3)

x 106/L

Lymphocytes

Known Unknown

28

29 %

Prolymphocytes

Known Unknown

30

31 %

LDH

Known Unknown

32

33 U/L µkat/L

Upper limit of normal for LDH:34 U/L µkat/L

Serum β2 microglobulin

Known Unknown

35

36 μg/dL mg/L nmol/L

Upper limit of normal for serum ß2 microglobulin:37 μg/dL mg/L nmol/L

Lymphocytes in bone marrow

Known Unknown

38

39 %

Leukemia cell type (may be determined at any time after diagnosis)

B-cell T-cell Unknown

40

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

41

Date sample collected:42 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

43

Specify method used44

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:45

NOTCH 1 mutation

Positive Negative Not done

46

P53 mutation

Positive Negative Not done

47

SF3B1 mutation

Positive Negative Not done

48

Other molecular marker

Positive Negative Not Done

49

Specify other molecular marker:50

Was documentation submitted to the CIBMTR?

Yes No

51

Was flow cytometry (immunophenotyping) performed?

yes no Unknown

52

CD5+

Positive Negative Not Done

53

CD19+

Positive Negative Not Done

54

CD20+

Positive Negative Not Done

55

CD23+

Positive Negative Not Done

56

CD38+

Positive Negative Not done

57

Specify percent positivity

≥30% positivity <30% positivity

58

SIg

Positive Negative Not done

59

ZAP-70 - mutated

Positive Negative Not done

60

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

61

Results of tests62

Abnormalities identified

No evaluable metaphases

No abnormalities

+12

Yes No

63

t(11;14)

yes no

64

Any other translocation of 14

Yes No

65

del(11q) / 11q–

yes no

66

del(13q) / 13q-

yes no

67

del (17p) / 17p-

yes no

68

Chromosome 6 abnormalities

Yes No

69

Chromosome 8 abnormalities

Yes No

70

Other abnormality

yes no

71

Specify other abnormality:72

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

73

Pre-HCT or Pre-Infusion Therapy Questions: 74 - 148

Was therapy given?

yes no Unknown

74

Line of Therapy (1) Questions: 75 - 148

Systemic therapy

yes no

75

Date therapy started

Known Unknown

76

Date started:77 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

78

Date stopped:79 __ __ __ __ - __ __- __ __

Number of cycles

Known Unknown

80

Number of cycles:81

Alemtuzumab (Campath)

yes no

82

Bendamustine

yes no

83

Chlorambucil (Leukeran)

yes no

84

Cladribine (2-CdA, Leustatin)

yes no

85

Corticosteroids

yes no

86

Cyclophosphamide (Cytoxan)

yes no

87

Cytarabine (Ara-C)

yes no

88

Doxorubicin (Adriamycin)

yes no

89

Etoposide (VP-16, VePesid)

yes no

90

Fludarabine (Fludara)

yes no

91

Gemcitabine (Gemzar)

yes no

92

Ibrutinib (Imbruvica)

Yes No

93

Idelalisib (Zydelig)

Yes No

94

Ifosfamide (Ifex)

yes no

95

Lenalidomide (Revlimid)

yes no

96

Nelarabine

Yes No

97

Nitrogen mustard (mustine)

yes no

98

Obinutuzumab

Yes No

99

Oblimersen

Yes No

100

Ofatumumab (Arzerra, HuMAX-CD20)

yes no

101

Pentostatin (Nipent)

yes no

102

Rituximab (anti-CD20, Rituxan)

yes no

103

Venetoclax

Yes No

104

Vincristine (VCR, Oncovin)

yes no

105

Other systemic therapy

yes no

106

Specify other systemic therapy:107

Was this line of therapy given for stem cell mobilization (priming)?

yes no

108

Radiation therapy

yes no

109

Date therapy started

Known Unknown

110

Date started:111 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

112

Date stopped:113 __ __ __ __ - __ __- __ __

Mediastinum

Yes No

114

Other site

yes no

115

Specify other site:116

Surgery

yes no

117

Date of surgery:118 __ __ __ __ - __ __- __ __

Splenectomy

yes no

119

Other site

yes no

120

Specify other site:121

Best response to line of therapy122

Complete
remission (CR)

­ no lymphadenopathy; no organomegaly; neutrophils ≥ 1.5 x 109/L; platelets > 100 x 109/L; hemoglobin > 11.0 g/dL; lymphocytes < 4 x 109/L;
bone marrow < 30% lymphocytes; absence of constitutional symptoms

Partial
remission
(PR)

- ≥ 50% decrease in peripheral blood lymphocyte count from pretreatment value; ≥ 50% reduction in lymphadenopathy if present pretreatment; ≥ 50%
reduction in liver and spleen size if enlarged pretreatment; one or more of the following: neutrophils ≥ 1.5 x 109/L or 50% improvement over baseline,
platelets > 100 x 109/L or 50% improvement over baseline, hemoglobin > 11.0 g/dL or 50% improvement over baseline

Stable disease (SD) - no change; not complete remission, partial remission, nor progressive disease

Progressive
disease
(Prog)

­ one or more of the following: ≥ 50% increase in the sum of the products of ≥ 2 lymph nodes (≥ 1 node must be ≥ 2 cm) or new nodes; ≥ 50%
increase in liver or spleen size, or new hepatomegaly or splenomegaly; ≥ 50% increase in absolute lymphocyte count to ≥ 5 x 109/L; transformation to
a more aggressive histology

Not assessed

Unknown

Date assessed:123 __ __ __ __ - __ __- __ __

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

124

Date sample collected:125 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

126

Specify method used127

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:128

NOTCH 1 mutation

Positive Negative Not done

129

P53 mutation

Positive Negative Not done

130

SF3B1 mutation

Positive Negative Not done

131

Other molecular marker

Positive Negative Not Done

132

Specify other molecular marker:133

Was the disease status assessed via flow cytometry? (minimum 4-color flow) (immunophenotyping)

yes no

134

Date sample collected:135 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

136

Was the disease status assessed by cytogenetic testing (karyotyping or FISH)?

yes no

137

Was the disease status assessed via FISH?

yes no

138

Date sample collected:139 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

140

Was the disease status assessed via karyotyping?

Yes No

141

Date sample collected:142 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

143

Was the disease status assessed by clinical / hematologic assessment?

yes no

144

Date assessed:145 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

146

Did disease relapse/progress following this line of therapy?

yes no

147

Date of relapse/progression:148 __ __ __ __ - __ __- __ __

Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 149 - 191

Did the recipient have known nodal involvement?

yes no

149

Specify the size of the largest nodal mass:150 cm x cm

Was extranodal disease present?

Yes No

151

Central nervous system (CNS)

Yes No

152

Lung

yes no

153

Other site

yes no

154

Specify other site:155

Prolymphocytes

Known Unknown

156

157 %

Serum β2 microglobulin

Known Unknown

158

159 μg/dL mg/L nmol/L

Upper limit of normal for serum ß2 microglobulin:160 μg/dL mg/L nmol/L

Lymphocytes in bone marrow

Known Unknown

161

162 %

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

163

Date sample collected:164 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

165

Specify method used166

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:167

NOTCH 1 mutation

Positive Negative Not done

168

P53 mutation

Positive Negative Not done

169

SF3B1 mutation

Positive Negative Not done

170

Other molecular marker

Positive Negative Not Done

171

Specify other molecular marker:172

Was documentation submitted to the CIBMTR?

Yes No

173

Was the disease status assessed via flow cytometry? (minimum 4-color flow) (immunophenotyping)

yes no

174

Date sample collected:175 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

176

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

177

Results of tests178

Abnormalities identified

No evaluable metaphases

No abnormalities

+12

Yes No

179

t(11;14)

yes no

180

Any other translocation of 14

Yes No

181

del(11q) / 11q–

yes no

182

del(13q) / 13q-

yes no

183

del (17p) / 17p-

yes no

184

Chromosome 6 abnormalities

Yes No

185

Chromosome 8 abnormalities

Yes No

186

Other abnormality

yes no

187

Specify other abnormality:188

Was the disease status assessed by clinical / hematologic assessment?

yes no

189

Date assessed:190 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

191

Disease Status at the Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 192 - 193

What was the disease status?192

Complete
remission (CR)

­ no lymphadenopathy; no organomegaly; neutrophils ≥ 1.5 x 109/L; platelets > 100 x 109/L; hemoglobin > 11.0 g/dL; lymphocytes < 4 x 109/L; bone
marrow < 30% lymphocytes; absence of constitutional symptoms

Partial
remission
(PR)

­ ≥ 50% decrease in peripheral blood lymphocyte count from pretreatment value; ≥ 50% reduction in lymphadenopathy if present pretreatment; ≥ 50% reduction
in liver and spleen size if enlarged pretreatment; one or more of the following: neutrophils ≥ 1.5 x 109/L or 50% improvement over baseline, platelets > 100 x
109/L or 50% improvement over baseline, hemoglobin > 11.0 g/dL or 50% improvement over baseline

Stable disease (SD) - no change; not complete remission, partial remission, nor progressive disease

Progressive
disease
(Prog)

­ one or more of the following: ≥ 50% increase in the sum of the products of ≥ 2 lymph nodes (≥ 1 node must be ≥ 2 cm) or new nodes; ≥ 50% increase in
liver or spleen size, or new hepatomegaly or splenomegaly; ≥ 50% increase in absolute lymphocyte count to ≥ 5 x 109/L; transformation to a more aggressive
histology

Untreated - no chemotherapy given in the 6 months prior to HCT

Not assessed

Date assessed:193 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

If this is a report of a second or subsequent transplant or cellular therapy for the same disease subtype and this baseline disease insert has not been completed for the previous
transplant or cellular therapy (e.g. patient was on TED track for the prior HCT, prior HCT was autologous with no consent, prior cellular therapy was not reported to the CIBMTR),
begin the form at question one.

If this is a report of a second or subsequent transplant or cellular therapy for a different disease, begin the form at question one.

Autoimmune disorder(s) at diagnosis:

Specify site(s) of disease:

Immunophenotype: (may be determined at any time after diagnosis)

Specify cytogenetic abnormalities identified at diagnosis:

Trisomy

Translocation

Deletion

Other

Specify site(s) of radiation therapy:

Specify site(s) of involvement:

Specify cytogenetic abnormalities detected at last evaluation prior to the start of the preparative regimen / infusion:

Trisomy

Translocation

Deletion

Other

Center: CRID: 

Form 2013 R3.0: Chronic Lymphocytic Leukemia (CLL) Pre-Infusion Data

CIBMTR Form 2013 revision 3.0 last updated Wednesday, November 16, 2016
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 2 / 8



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 21

What was the date of diagnosis?1 __ __ __ __ - __ __- __ __

Was documentation submitted to the CIBMTR? (e.g. pathology report used for diagnosis)

Yes No

2

Did a histologic transformation occur at any time after CLL diagnosis?

yes no

3

Date of transformation:4 __ __ __ __ - __ __- __ __

Specify the disease classification after transformation5

Diffuse large B-cell lymphoma (Richter syndrome) Also complete CIBMTR form 2018 - LYM

Other disease classification

Specify other disease classification:6

Was documentation submitted to the CIBMTR? (e.g. pathology report at transformation)

Yes No

7

Immune hemolytic anemia

Yes No Unknown

8

Immune thrombocytopenia

Yes No Unknown

9

Other

Yes No Unknown

10

Specify other autoimmune disorder:11

Rai stage (at diagnosis)

Known Unknown

12

What was the Rai stage? (at diagnosis)13

Stage 0 - Low risk - lymphocytosis (> 15,000 x 109/L) in blood or bone marrow only without lymphadenopathy, hepatosplenomegaly, anemia or thrombocytopenia

Stage I - Intermediate risk - lymphocytosis plus enlarged lymph nodes (lymphadenopathy) without hepatosplenomegaly, anemia or thrombocytopenia

Stage II - Intermediate risk - lymphocytosis plus enlarged liver or spleen with or without lymphadenopathy

Stage III - High risk - lymphocytosis plus anemia (Hgb < 11.0 g/dL) with or without enlarged liver, spleen, or lymph nodes

Stage IV - High risk - lymphocytosis plus thrombocytopenia (platelet count < 100 x 109/L) with or without anemia or enlarged liver, spleen, or lymph nodes

Binet stage (at diagnosis)

Known Unknown

14

What was the Binet stage? (at diagnosis) (Five lymphoid bearing areas are possible: axillary, cervical, inguino-femoral, liver, and spleen.)15

Stage A - two or fewer lymphoid bearing areas enlarged, without anemia or thrombocytopenia

Stage B - three or more lymphoid bearing areas enlarged, without anemia or thrombocytopenia

Stage C - presence of anemia (Hgb < 10.0 g/dL) or thrombocytopenia (platelet count < 100 x 109/L)

Were systemic symptoms (B symptoms) present? (unexplained fever > 38° C; or night sweats; unexplained weight loss > 10% of body weight in six months before diagnosis)

yes no Unknown

16

Was extranodal disease present?

Yes No

17

Central nervous system (CNS)

Yes No

18

Lung

yes no

19

Other site

yes no

20

Specify other site:21

Laboratory Studies at Diagnosis Questions: 22 - 73

WBC

Known Unknown

22

23 x 109/L (x 103/mm3)

x 106/L

Hemoglobin (untransfused)

Known Unknown

24

25 g/dL g/L mmol/L

Platelets (untransfused)

Known Unknown

26

27 x 109/L (x 103/mm3)

x 106/L

Lymphocytes

Known Unknown

28

29 %

Prolymphocytes

Known Unknown

30

31 %

LDH

Known Unknown

32

33 U/L µkat/L

Upper limit of normal for LDH:34 U/L µkat/L

Serum β2 microglobulin

Known Unknown

35

36 μg/dL mg/L nmol/L

Upper limit of normal for serum ß2 microglobulin:37 μg/dL mg/L nmol/L

Lymphocytes in bone marrow

Known Unknown

38

39 %

Leukemia cell type (may be determined at any time after diagnosis)

B-cell T-cell Unknown

40

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

41

Date sample collected:42 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

43

Specify method used44

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:45

NOTCH 1 mutation

Positive Negative Not done

46

P53 mutation

Positive Negative Not done

47

SF3B1 mutation

Positive Negative Not done

48

Other molecular marker

Positive Negative Not Done

49

Specify other molecular marker:50

Was documentation submitted to the CIBMTR?

Yes No

51

Was flow cytometry (immunophenotyping) performed?

yes no Unknown

52

CD5+

Positive Negative Not Done

53

CD19+

Positive Negative Not Done

54

CD20+

Positive Negative Not Done

55

CD23+

Positive Negative Not Done

56

CD38+

Positive Negative Not done

57

Specify percent positivity

≥30% positivity <30% positivity

58

SIg

Positive Negative Not done

59

ZAP-70 - mutated

Positive Negative Not done

60

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

61

Results of tests62

Abnormalities identified

No evaluable metaphases

No abnormalities

+12

Yes No

63

t(11;14)

yes no

64

Any other translocation of 14

Yes No

65

del(11q) / 11q–

yes no

66

del(13q) / 13q-

yes no

67

del (17p) / 17p-

yes no

68

Chromosome 6 abnormalities

Yes No

69

Chromosome 8 abnormalities

Yes No

70

Other abnormality

yes no

71

Specify other abnormality:72

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

73

Pre-HCT or Pre-Infusion Therapy Questions: 74 - 148

Was therapy given?

yes no Unknown

74

Line of Therapy (1) Questions: 75 - 148

Systemic therapy

yes no

75

Date therapy started

Known Unknown

76

Date started:77 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

78

Date stopped:79 __ __ __ __ - __ __- __ __

Number of cycles

Known Unknown

80

Number of cycles:81

Alemtuzumab (Campath)

yes no

82

Bendamustine

yes no

83

Chlorambucil (Leukeran)

yes no

84

Cladribine (2-CdA, Leustatin)

yes no

85

Corticosteroids

yes no

86

Cyclophosphamide (Cytoxan)

yes no

87

Cytarabine (Ara-C)

yes no

88

Doxorubicin (Adriamycin)

yes no

89

Etoposide (VP-16, VePesid)

yes no

90

Fludarabine (Fludara)

yes no

91

Gemcitabine (Gemzar)

yes no

92

Ibrutinib (Imbruvica)

Yes No

93

Idelalisib (Zydelig)

Yes No

94

Ifosfamide (Ifex)

yes no

95

Lenalidomide (Revlimid)

yes no

96

Nelarabine

Yes No

97

Nitrogen mustard (mustine)

yes no

98

Obinutuzumab

Yes No

99

Oblimersen

Yes No

100

Ofatumumab (Arzerra, HuMAX-CD20)

yes no

101

Pentostatin (Nipent)

yes no

102

Rituximab (anti-CD20, Rituxan)

yes no

103

Venetoclax

Yes No

104

Vincristine (VCR, Oncovin)

yes no

105

Other systemic therapy

yes no

106

Specify other systemic therapy:107

Was this line of therapy given for stem cell mobilization (priming)?

yes no

108

Radiation therapy

yes no

109

Date therapy started

Known Unknown

110

Date started:111 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

112

Date stopped:113 __ __ __ __ - __ __- __ __

Mediastinum

Yes No

114

Other site

yes no

115

Specify other site:116

Surgery

yes no

117

Date of surgery:118 __ __ __ __ - __ __- __ __

Splenectomy

yes no

119

Other site

yes no

120

Specify other site:121

Best response to line of therapy122

Complete
remission (CR)

­ no lymphadenopathy; no organomegaly; neutrophils ≥ 1.5 x 109/L; platelets > 100 x 109/L; hemoglobin > 11.0 g/dL; lymphocytes < 4 x 109/L;
bone marrow < 30% lymphocytes; absence of constitutional symptoms

Partial
remission
(PR)

- ≥ 50% decrease in peripheral blood lymphocyte count from pretreatment value; ≥ 50% reduction in lymphadenopathy if present pretreatment; ≥ 50%
reduction in liver and spleen size if enlarged pretreatment; one or more of the following: neutrophils ≥ 1.5 x 109/L or 50% improvement over baseline,
platelets > 100 x 109/L or 50% improvement over baseline, hemoglobin > 11.0 g/dL or 50% improvement over baseline

Stable disease (SD) - no change; not complete remission, partial remission, nor progressive disease

Progressive
disease
(Prog)

­ one or more of the following: ≥ 50% increase in the sum of the products of ≥ 2 lymph nodes (≥ 1 node must be ≥ 2 cm) or new nodes; ≥ 50%
increase in liver or spleen size, or new hepatomegaly or splenomegaly; ≥ 50% increase in absolute lymphocyte count to ≥ 5 x 109/L; transformation to
a more aggressive histology

Not assessed

Unknown

Date assessed:123 __ __ __ __ - __ __- __ __

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

124

Date sample collected:125 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

126

Specify method used127

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:128

NOTCH 1 mutation

Positive Negative Not done

129

P53 mutation

Positive Negative Not done

130

SF3B1 mutation

Positive Negative Not done

131

Other molecular marker

Positive Negative Not Done

132

Specify other molecular marker:133

Was the disease status assessed via flow cytometry? (minimum 4-color flow) (immunophenotyping)

yes no

134

Date sample collected:135 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

136

Was the disease status assessed by cytogenetic testing (karyotyping or FISH)?

yes no

137

Was the disease status assessed via FISH?

yes no

138

Date sample collected:139 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

140

Was the disease status assessed via karyotyping?

Yes No

141

Date sample collected:142 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

143

Was the disease status assessed by clinical / hematologic assessment?

yes no

144

Date assessed:145 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

146

Did disease relapse/progress following this line of therapy?

yes no

147

Date of relapse/progression:148 __ __ __ __ - __ __- __ __

Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 149 - 191

Did the recipient have known nodal involvement?

yes no

149

Specify the size of the largest nodal mass:150 cm x cm

Was extranodal disease present?

Yes No

151

Central nervous system (CNS)

Yes No

152

Lung

yes no

153

Other site

yes no

154

Specify other site:155

Prolymphocytes

Known Unknown

156

157 %

Serum β2 microglobulin

Known Unknown

158

159 μg/dL mg/L nmol/L

Upper limit of normal for serum ß2 microglobulin:160 μg/dL mg/L nmol/L

Lymphocytes in bone marrow

Known Unknown

161

162 %

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

163

Date sample collected:164 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

165

Specify method used166

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:167

NOTCH 1 mutation

Positive Negative Not done

168

P53 mutation

Positive Negative Not done

169

SF3B1 mutation

Positive Negative Not done

170

Other molecular marker

Positive Negative Not Done

171

Specify other molecular marker:172

Was documentation submitted to the CIBMTR?

Yes No

173

Was the disease status assessed via flow cytometry? (minimum 4-color flow) (immunophenotyping)

yes no

174

Date sample collected:175 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

176

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

177

Results of tests178

Abnormalities identified

No evaluable metaphases

No abnormalities

+12

Yes No

179

t(11;14)

yes no

180

Any other translocation of 14

Yes No

181

del(11q) / 11q–

yes no

182

del(13q) / 13q-

yes no

183

del (17p) / 17p-

yes no

184

Chromosome 6 abnormalities

Yes No

185

Chromosome 8 abnormalities

Yes No

186

Other abnormality

yes no

187

Specify other abnormality:188

Was the disease status assessed by clinical / hematologic assessment?

yes no

189

Date assessed:190 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

191

Disease Status at the Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 192 - 193

What was the disease status?192

Complete
remission (CR)

­ no lymphadenopathy; no organomegaly; neutrophils ≥ 1.5 x 109/L; platelets > 100 x 109/L; hemoglobin > 11.0 g/dL; lymphocytes < 4 x 109/L; bone
marrow < 30% lymphocytes; absence of constitutional symptoms

Partial
remission
(PR)

­ ≥ 50% decrease in peripheral blood lymphocyte count from pretreatment value; ≥ 50% reduction in lymphadenopathy if present pretreatment; ≥ 50% reduction
in liver and spleen size if enlarged pretreatment; one or more of the following: neutrophils ≥ 1.5 x 109/L or 50% improvement over baseline, platelets > 100 x
109/L or 50% improvement over baseline, hemoglobin > 11.0 g/dL or 50% improvement over baseline

Stable disease (SD) - no change; not complete remission, partial remission, nor progressive disease

Progressive
disease
(Prog)

­ one or more of the following: ≥ 50% increase in the sum of the products of ≥ 2 lymph nodes (≥ 1 node must be ≥ 2 cm) or new nodes; ≥ 50% increase in
liver or spleen size, or new hepatomegaly or splenomegaly; ≥ 50% increase in absolute lymphocyte count to ≥ 5 x 109/L; transformation to a more aggressive
histology

Untreated - no chemotherapy given in the 6 months prior to HCT

Not assessed

Date assessed:193 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

If this is a report of a second or subsequent transplant or cellular therapy for the same disease subtype and this baseline disease insert has not been completed for the previous
transplant or cellular therapy (e.g. patient was on TED track for the prior HCT, prior HCT was autologous with no consent, prior cellular therapy was not reported to the CIBMTR),
begin the form at question one.

If this is a report of a second or subsequent transplant or cellular therapy for a different disease, begin the form at question one.

Autoimmune disorder(s) at diagnosis:

Specify site(s) of disease:

Immunophenotype: (may be determined at any time after diagnosis)

Specify cytogenetic abnormalities identified at diagnosis:

Trisomy

Translocation

Deletion

Other

Specify site(s) of radiation therapy:

Specify site(s) of involvement:

Specify cytogenetic abnormalities detected at last evaluation prior to the start of the preparative regimen / infusion:

Trisomy

Translocation

Deletion

Other

Center: CRID: 

Form 2013 R3.0: Chronic Lymphocytic Leukemia (CLL) Pre-Infusion Data

CIBMTR Form 2013 revision 3.0 last updated Wednesday, November 16, 2016
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 3 / 8



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 21

What was the date of diagnosis?1 __ __ __ __ - __ __- __ __

Was documentation submitted to the CIBMTR? (e.g. pathology report used for diagnosis)

Yes No

2

Did a histologic transformation occur at any time after CLL diagnosis?

yes no

3

Date of transformation:4 __ __ __ __ - __ __- __ __

Specify the disease classification after transformation5

Diffuse large B-cell lymphoma (Richter syndrome) Also complete CIBMTR form 2018 - LYM

Other disease classification

Specify other disease classification:6

Was documentation submitted to the CIBMTR? (e.g. pathology report at transformation)

Yes No

7

Immune hemolytic anemia

Yes No Unknown

8

Immune thrombocytopenia

Yes No Unknown

9

Other

Yes No Unknown

10

Specify other autoimmune disorder:11

Rai stage (at diagnosis)

Known Unknown

12

What was the Rai stage? (at diagnosis)13

Stage 0 - Low risk - lymphocytosis (> 15,000 x 109/L) in blood or bone marrow only without lymphadenopathy, hepatosplenomegaly, anemia or thrombocytopenia

Stage I - Intermediate risk - lymphocytosis plus enlarged lymph nodes (lymphadenopathy) without hepatosplenomegaly, anemia or thrombocytopenia

Stage II - Intermediate risk - lymphocytosis plus enlarged liver or spleen with or without lymphadenopathy

Stage III - High risk - lymphocytosis plus anemia (Hgb < 11.0 g/dL) with or without enlarged liver, spleen, or lymph nodes

Stage IV - High risk - lymphocytosis plus thrombocytopenia (platelet count < 100 x 109/L) with or without anemia or enlarged liver, spleen, or lymph nodes

Binet stage (at diagnosis)

Known Unknown

14

What was the Binet stage? (at diagnosis) (Five lymphoid bearing areas are possible: axillary, cervical, inguino-femoral, liver, and spleen.)15

Stage A - two or fewer lymphoid bearing areas enlarged, without anemia or thrombocytopenia

Stage B - three or more lymphoid bearing areas enlarged, without anemia or thrombocytopenia

Stage C - presence of anemia (Hgb < 10.0 g/dL) or thrombocytopenia (platelet count < 100 x 109/L)

Were systemic symptoms (B symptoms) present? (unexplained fever > 38° C; or night sweats; unexplained weight loss > 10% of body weight in six months before diagnosis)

yes no Unknown

16

Was extranodal disease present?

Yes No

17

Central nervous system (CNS)

Yes No

18

Lung

yes no

19

Other site

yes no

20

Specify other site:21

Laboratory Studies at Diagnosis Questions: 22 - 73

WBC

Known Unknown

22

23 x 109/L (x 103/mm3)

x 106/L

Hemoglobin (untransfused)

Known Unknown

24

25 g/dL g/L mmol/L

Platelets (untransfused)

Known Unknown

26

27 x 109/L (x 103/mm3)

x 106/L

Lymphocytes

Known Unknown

28

29 %

Prolymphocytes

Known Unknown

30

31 %

LDH

Known Unknown

32

33 U/L µkat/L

Upper limit of normal for LDH:34 U/L µkat/L

Serum β2 microglobulin

Known Unknown

35

36 μg/dL mg/L nmol/L

Upper limit of normal for serum ß2 microglobulin:37 μg/dL mg/L nmol/L

Lymphocytes in bone marrow

Known Unknown

38

39 %

Leukemia cell type (may be determined at any time after diagnosis)

B-cell T-cell Unknown

40

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

41

Date sample collected:42 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

43

Specify method used44

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:45

NOTCH 1 mutation

Positive Negative Not done

46

P53 mutation

Positive Negative Not done

47

SF3B1 mutation

Positive Negative Not done

48

Other molecular marker

Positive Negative Not Done

49

Specify other molecular marker:50

Was documentation submitted to the CIBMTR?

Yes No

51

Was flow cytometry (immunophenotyping) performed?

yes no Unknown

52

CD5+

Positive Negative Not Done

53

CD19+

Positive Negative Not Done

54

CD20+

Positive Negative Not Done

55

CD23+

Positive Negative Not Done

56

CD38+

Positive Negative Not done

57

Specify percent positivity

≥30% positivity <30% positivity

58

SIg

Positive Negative Not done

59

ZAP-70 - mutated

Positive Negative Not done

60

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

61

Results of tests62

Abnormalities identified

No evaluable metaphases

No abnormalities

+12

Yes No

63

t(11;14)

yes no

64

Any other translocation of 14

Yes No

65

del(11q) / 11q–

yes no

66

del(13q) / 13q-

yes no

67

del (17p) / 17p-

yes no

68

Chromosome 6 abnormalities

Yes No

69

Chromosome 8 abnormalities

Yes No

70

Other abnormality

yes no

71

Specify other abnormality:72

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

73

Pre-HCT or Pre-Infusion Therapy Questions: 74 - 148

Was therapy given?

yes no Unknown

74

Line of Therapy (1) Questions: 75 - 148

Systemic therapy

yes no

75

Date therapy started

Known Unknown

76

Date started:77 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

78

Date stopped:79 __ __ __ __ - __ __- __ __

Number of cycles

Known Unknown

80

Number of cycles:81

Alemtuzumab (Campath)

yes no

82

Bendamustine

yes no

83

Chlorambucil (Leukeran)

yes no

84

Cladribine (2-CdA, Leustatin)

yes no

85

Corticosteroids

yes no

86

Cyclophosphamide (Cytoxan)

yes no

87

Cytarabine (Ara-C)

yes no

88

Doxorubicin (Adriamycin)

yes no

89

Etoposide (VP-16, VePesid)

yes no

90

Fludarabine (Fludara)

yes no

91

Gemcitabine (Gemzar)

yes no

92

Ibrutinib (Imbruvica)

Yes No

93

Idelalisib (Zydelig)

Yes No

94

Ifosfamide (Ifex)

yes no

95

Lenalidomide (Revlimid)

yes no

96

Nelarabine

Yes No

97

Nitrogen mustard (mustine)

yes no

98

Obinutuzumab

Yes No

99

Oblimersen

Yes No

100

Ofatumumab (Arzerra, HuMAX-CD20)

yes no

101

Pentostatin (Nipent)

yes no

102

Rituximab (anti-CD20, Rituxan)

yes no

103

Venetoclax

Yes No

104

Vincristine (VCR, Oncovin)

yes no

105

Other systemic therapy

yes no

106

Specify other systemic therapy:107

Was this line of therapy given for stem cell mobilization (priming)?

yes no

108

Radiation therapy

yes no

109

Date therapy started

Known Unknown

110

Date started:111 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

112

Date stopped:113 __ __ __ __ - __ __- __ __

Mediastinum

Yes No

114

Other site

yes no

115

Specify other site:116

Surgery

yes no

117

Date of surgery:118 __ __ __ __ - __ __- __ __

Splenectomy

yes no

119

Other site

yes no

120

Specify other site:121

Best response to line of therapy122

Complete
remission (CR)

­ no lymphadenopathy; no organomegaly; neutrophils ≥ 1.5 x 109/L; platelets > 100 x 109/L; hemoglobin > 11.0 g/dL; lymphocytes < 4 x 109/L;
bone marrow < 30% lymphocytes; absence of constitutional symptoms

Partial
remission
(PR)

- ≥ 50% decrease in peripheral blood lymphocyte count from pretreatment value; ≥ 50% reduction in lymphadenopathy if present pretreatment; ≥ 50%
reduction in liver and spleen size if enlarged pretreatment; one or more of the following: neutrophils ≥ 1.5 x 109/L or 50% improvement over baseline,
platelets > 100 x 109/L or 50% improvement over baseline, hemoglobin > 11.0 g/dL or 50% improvement over baseline

Stable disease (SD) - no change; not complete remission, partial remission, nor progressive disease

Progressive
disease
(Prog)

­ one or more of the following: ≥ 50% increase in the sum of the products of ≥ 2 lymph nodes (≥ 1 node must be ≥ 2 cm) or new nodes; ≥ 50%
increase in liver or spleen size, or new hepatomegaly or splenomegaly; ≥ 50% increase in absolute lymphocyte count to ≥ 5 x 109/L; transformation to
a more aggressive histology

Not assessed

Unknown

Date assessed:123 __ __ __ __ - __ __- __ __

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

124

Date sample collected:125 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

126

Specify method used127

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:128

NOTCH 1 mutation

Positive Negative Not done

129

P53 mutation

Positive Negative Not done

130

SF3B1 mutation

Positive Negative Not done

131

Other molecular marker

Positive Negative Not Done

132

Specify other molecular marker:133

Was the disease status assessed via flow cytometry? (minimum 4-color flow) (immunophenotyping)

yes no

134

Date sample collected:135 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

136

Was the disease status assessed by cytogenetic testing (karyotyping or FISH)?

yes no

137

Was the disease status assessed via FISH?

yes no

138

Date sample collected:139 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

140

Was the disease status assessed via karyotyping?

Yes No

141

Date sample collected:142 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

143

Was the disease status assessed by clinical / hematologic assessment?

yes no

144

Date assessed:145 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

146

Did disease relapse/progress following this line of therapy?

yes no

147

Date of relapse/progression:148 __ __ __ __ - __ __- __ __

Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 149 - 191

Did the recipient have known nodal involvement?

yes no

149

Specify the size of the largest nodal mass:150 cm x cm

Was extranodal disease present?

Yes No

151

Central nervous system (CNS)

Yes No

152

Lung

yes no

153

Other site

yes no

154

Specify other site:155

Prolymphocytes

Known Unknown

156

157 %

Serum β2 microglobulin

Known Unknown

158

159 μg/dL mg/L nmol/L

Upper limit of normal for serum ß2 microglobulin:160 μg/dL mg/L nmol/L

Lymphocytes in bone marrow

Known Unknown

161

162 %

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

163

Date sample collected:164 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

165

Specify method used166

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:167

NOTCH 1 mutation

Positive Negative Not done

168

P53 mutation

Positive Negative Not done

169

SF3B1 mutation

Positive Negative Not done

170

Other molecular marker

Positive Negative Not Done

171

Specify other molecular marker:172

Was documentation submitted to the CIBMTR?

Yes No

173

Was the disease status assessed via flow cytometry? (minimum 4-color flow) (immunophenotyping)

yes no

174

Date sample collected:175 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

176

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

177

Results of tests178

Abnormalities identified

No evaluable metaphases

No abnormalities

+12

Yes No

179

t(11;14)

yes no

180

Any other translocation of 14

Yes No

181

del(11q) / 11q–

yes no

182

del(13q) / 13q-

yes no

183

del (17p) / 17p-

yes no

184

Chromosome 6 abnormalities

Yes No

185

Chromosome 8 abnormalities

Yes No

186

Other abnormality

yes no

187

Specify other abnormality:188

Was the disease status assessed by clinical / hematologic assessment?

yes no

189

Date assessed:190 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

191

Disease Status at the Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 192 - 193

What was the disease status?192

Complete
remission (CR)

­ no lymphadenopathy; no organomegaly; neutrophils ≥ 1.5 x 109/L; platelets > 100 x 109/L; hemoglobin > 11.0 g/dL; lymphocytes < 4 x 109/L; bone
marrow < 30% lymphocytes; absence of constitutional symptoms

Partial
remission
(PR)

­ ≥ 50% decrease in peripheral blood lymphocyte count from pretreatment value; ≥ 50% reduction in lymphadenopathy if present pretreatment; ≥ 50% reduction
in liver and spleen size if enlarged pretreatment; one or more of the following: neutrophils ≥ 1.5 x 109/L or 50% improvement over baseline, platelets > 100 x
109/L or 50% improvement over baseline, hemoglobin > 11.0 g/dL or 50% improvement over baseline

Stable disease (SD) - no change; not complete remission, partial remission, nor progressive disease

Progressive
disease
(Prog)

­ one or more of the following: ≥ 50% increase in the sum of the products of ≥ 2 lymph nodes (≥ 1 node must be ≥ 2 cm) or new nodes; ≥ 50% increase in
liver or spleen size, or new hepatomegaly or splenomegaly; ≥ 50% increase in absolute lymphocyte count to ≥ 5 x 109/L; transformation to a more aggressive
histology

Untreated - no chemotherapy given in the 6 months prior to HCT

Not assessed

Date assessed:193 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

If this is a report of a second or subsequent transplant or cellular therapy for the same disease subtype and this baseline disease insert has not been completed for the previous
transplant or cellular therapy (e.g. patient was on TED track for the prior HCT, prior HCT was autologous with no consent, prior cellular therapy was not reported to the CIBMTR),
begin the form at question one.

If this is a report of a second or subsequent transplant or cellular therapy for a different disease, begin the form at question one.

Autoimmune disorder(s) at diagnosis:

Specify site(s) of disease:

Immunophenotype: (may be determined at any time after diagnosis)

Specify cytogenetic abnormalities identified at diagnosis:

Trisomy

Translocation

Deletion

Other

Specify site(s) of radiation therapy:

Specify site(s) of involvement:

Specify cytogenetic abnormalities detected at last evaluation prior to the start of the preparative regimen / infusion:

Trisomy

Translocation

Deletion

Other

Center: CRID: 

Form 2013 R3.0: Chronic Lymphocytic Leukemia (CLL) Pre-Infusion Data

CIBMTR Form 2013 revision 3.0 last updated Wednesday, November 16, 2016
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 4 / 8



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 21

What was the date of diagnosis?1 __ __ __ __ - __ __- __ __

Was documentation submitted to the CIBMTR? (e.g. pathology report used for diagnosis)

Yes No

2

Did a histologic transformation occur at any time after CLL diagnosis?

yes no

3

Date of transformation:4 __ __ __ __ - __ __- __ __

Specify the disease classification after transformation5

Diffuse large B-cell lymphoma (Richter syndrome) Also complete CIBMTR form 2018 - LYM

Other disease classification

Specify other disease classification:6

Was documentation submitted to the CIBMTR? (e.g. pathology report at transformation)

Yes No

7

Immune hemolytic anemia

Yes No Unknown

8

Immune thrombocytopenia

Yes No Unknown

9

Other

Yes No Unknown

10

Specify other autoimmune disorder:11

Rai stage (at diagnosis)

Known Unknown

12

What was the Rai stage? (at diagnosis)13

Stage 0 - Low risk - lymphocytosis (> 15,000 x 109/L) in blood or bone marrow only without lymphadenopathy, hepatosplenomegaly, anemia or thrombocytopenia

Stage I - Intermediate risk - lymphocytosis plus enlarged lymph nodes (lymphadenopathy) without hepatosplenomegaly, anemia or thrombocytopenia

Stage II - Intermediate risk - lymphocytosis plus enlarged liver or spleen with or without lymphadenopathy

Stage III - High risk - lymphocytosis plus anemia (Hgb < 11.0 g/dL) with or without enlarged liver, spleen, or lymph nodes

Stage IV - High risk - lymphocytosis plus thrombocytopenia (platelet count < 100 x 109/L) with or without anemia or enlarged liver, spleen, or lymph nodes

Binet stage (at diagnosis)

Known Unknown

14

What was the Binet stage? (at diagnosis) (Five lymphoid bearing areas are possible: axillary, cervical, inguino-femoral, liver, and spleen.)15

Stage A - two or fewer lymphoid bearing areas enlarged, without anemia or thrombocytopenia

Stage B - three or more lymphoid bearing areas enlarged, without anemia or thrombocytopenia

Stage C - presence of anemia (Hgb < 10.0 g/dL) or thrombocytopenia (platelet count < 100 x 109/L)

Were systemic symptoms (B symptoms) present? (unexplained fever > 38° C; or night sweats; unexplained weight loss > 10% of body weight in six months before diagnosis)

yes no Unknown

16

Was extranodal disease present?

Yes No

17

Central nervous system (CNS)

Yes No

18

Lung

yes no

19

Other site

yes no

20

Specify other site:21

Laboratory Studies at Diagnosis Questions: 22 - 73

WBC

Known Unknown

22

23 x 109/L (x 103/mm3)

x 106/L

Hemoglobin (untransfused)

Known Unknown

24

25 g/dL g/L mmol/L

Platelets (untransfused)

Known Unknown

26

27 x 109/L (x 103/mm3)

x 106/L

Lymphocytes

Known Unknown

28

29 %

Prolymphocytes

Known Unknown

30

31 %

LDH

Known Unknown

32

33 U/L µkat/L

Upper limit of normal for LDH:34 U/L µkat/L

Serum β2 microglobulin

Known Unknown

35

36 μg/dL mg/L nmol/L

Upper limit of normal for serum ß2 microglobulin:37 μg/dL mg/L nmol/L

Lymphocytes in bone marrow

Known Unknown

38

39 %

Leukemia cell type (may be determined at any time after diagnosis)

B-cell T-cell Unknown

40

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

41

Date sample collected:42 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

43

Specify method used44

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:45

NOTCH 1 mutation

Positive Negative Not done

46

P53 mutation

Positive Negative Not done

47

SF3B1 mutation

Positive Negative Not done

48

Other molecular marker

Positive Negative Not Done

49

Specify other molecular marker:50

Was documentation submitted to the CIBMTR?

Yes No

51

Was flow cytometry (immunophenotyping) performed?

yes no Unknown

52

CD5+

Positive Negative Not Done

53

CD19+

Positive Negative Not Done

54

CD20+

Positive Negative Not Done

55

CD23+

Positive Negative Not Done

56

CD38+

Positive Negative Not done

57

Specify percent positivity

≥30% positivity <30% positivity

58

SIg

Positive Negative Not done

59

ZAP-70 - mutated

Positive Negative Not done

60

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

61

Results of tests62

Abnormalities identified

No evaluable metaphases

No abnormalities

+12

Yes No

63

t(11;14)

yes no

64

Any other translocation of 14

Yes No

65

del(11q) / 11q–

yes no

66

del(13q) / 13q-

yes no

67

del (17p) / 17p-

yes no

68

Chromosome 6 abnormalities

Yes No

69

Chromosome 8 abnormalities

Yes No

70

Other abnormality

yes no

71

Specify other abnormality:72

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

73

Pre-HCT or Pre-Infusion Therapy Questions: 74 - 148

Was therapy given?

yes no Unknown

74

Line of Therapy (1) Questions: 75 - 148

Systemic therapy

yes no

75

Date therapy started

Known Unknown

76

Date started:77 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

78

Date stopped:79 __ __ __ __ - __ __- __ __

Number of cycles

Known Unknown

80

Number of cycles:81

Alemtuzumab (Campath)

yes no

82

Bendamustine

yes no

83

Chlorambucil (Leukeran)

yes no

84

Cladribine (2-CdA, Leustatin)

yes no

85

Corticosteroids

yes no

86

Cyclophosphamide (Cytoxan)

yes no

87

Cytarabine (Ara-C)

yes no

88

Doxorubicin (Adriamycin)

yes no

89

Etoposide (VP-16, VePesid)

yes no

90

Fludarabine (Fludara)

yes no

91

Gemcitabine (Gemzar)

yes no

92

Ibrutinib (Imbruvica)

Yes No

93

Idelalisib (Zydelig)

Yes No

94

Ifosfamide (Ifex)

yes no

95

Lenalidomide (Revlimid)

yes no

96

Nelarabine

Yes No

97

Nitrogen mustard (mustine)

yes no

98

Obinutuzumab

Yes No

99

Oblimersen

Yes No

100

Ofatumumab (Arzerra, HuMAX-CD20)

yes no

101

Pentostatin (Nipent)

yes no

102

Rituximab (anti-CD20, Rituxan)

yes no

103

Venetoclax

Yes No

104

Vincristine (VCR, Oncovin)

yes no

105

Other systemic therapy

yes no

106

Specify other systemic therapy:107

Was this line of therapy given for stem cell mobilization (priming)?

yes no

108

Radiation therapy

yes no

109

Date therapy started

Known Unknown

110

Date started:111 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

112

Date stopped:113 __ __ __ __ - __ __- __ __

Mediastinum

Yes No

114

Other site

yes no

115

Specify other site:116

Surgery

yes no

117

Date of surgery:118 __ __ __ __ - __ __- __ __

Splenectomy

yes no

119

Other site

yes no

120

Specify other site:121

Best response to line of therapy122

Complete
remission (CR)

­ no lymphadenopathy; no organomegaly; neutrophils ≥ 1.5 x 109/L; platelets > 100 x 109/L; hemoglobin > 11.0 g/dL; lymphocytes < 4 x 109/L;
bone marrow < 30% lymphocytes; absence of constitutional symptoms

Partial
remission
(PR)

- ≥ 50% decrease in peripheral blood lymphocyte count from pretreatment value; ≥ 50% reduction in lymphadenopathy if present pretreatment; ≥ 50%
reduction in liver and spleen size if enlarged pretreatment; one or more of the following: neutrophils ≥ 1.5 x 109/L or 50% improvement over baseline,
platelets > 100 x 109/L or 50% improvement over baseline, hemoglobin > 11.0 g/dL or 50% improvement over baseline

Stable disease (SD) - no change; not complete remission, partial remission, nor progressive disease

Progressive
disease
(Prog)

­ one or more of the following: ≥ 50% increase in the sum of the products of ≥ 2 lymph nodes (≥ 1 node must be ≥ 2 cm) or new nodes; ≥ 50%
increase in liver or spleen size, or new hepatomegaly or splenomegaly; ≥ 50% increase in absolute lymphocyte count to ≥ 5 x 109/L; transformation to
a more aggressive histology

Not assessed

Unknown

Date assessed:123 __ __ __ __ - __ __- __ __

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

124

Date sample collected:125 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

126

Specify method used127

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:128

NOTCH 1 mutation

Positive Negative Not done

129

P53 mutation

Positive Negative Not done

130

SF3B1 mutation

Positive Negative Not done

131

Other molecular marker

Positive Negative Not Done

132

Specify other molecular marker:133

Was the disease status assessed via flow cytometry? (minimum 4-color flow) (immunophenotyping)

yes no

134

Date sample collected:135 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

136

Was the disease status assessed by cytogenetic testing (karyotyping or FISH)?

yes no

137

Was the disease status assessed via FISH?

yes no

138

Date sample collected:139 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

140

Was the disease status assessed via karyotyping?

Yes No

141

Date sample collected:142 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

143

Was the disease status assessed by clinical / hematologic assessment?

yes no

144

Date assessed:145 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

146

Did disease relapse/progress following this line of therapy?

yes no

147

Date of relapse/progression:148 __ __ __ __ - __ __- __ __

Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 149 - 191

Did the recipient have known nodal involvement?

yes no

149

Specify the size of the largest nodal mass:150 cm x cm

Was extranodal disease present?

Yes No

151

Central nervous system (CNS)

Yes No

152

Lung

yes no

153

Other site

yes no

154

Specify other site:155

Prolymphocytes

Known Unknown

156

157 %

Serum β2 microglobulin

Known Unknown

158

159 μg/dL mg/L nmol/L

Upper limit of normal for serum ß2 microglobulin:160 μg/dL mg/L nmol/L

Lymphocytes in bone marrow

Known Unknown

161

162 %

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

163

Date sample collected:164 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

165

Specify method used166

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:167

NOTCH 1 mutation

Positive Negative Not done

168

P53 mutation

Positive Negative Not done

169

SF3B1 mutation

Positive Negative Not done

170

Other molecular marker

Positive Negative Not Done

171

Specify other molecular marker:172

Was documentation submitted to the CIBMTR?

Yes No

173

Was the disease status assessed via flow cytometry? (minimum 4-color flow) (immunophenotyping)

yes no

174

Date sample collected:175 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

176

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

177

Results of tests178

Abnormalities identified

No evaluable metaphases

No abnormalities

+12

Yes No

179

t(11;14)

yes no

180

Any other translocation of 14

Yes No

181

del(11q) / 11q–

yes no

182

del(13q) / 13q-

yes no

183

del (17p) / 17p-

yes no

184

Chromosome 6 abnormalities

Yes No

185

Chromosome 8 abnormalities

Yes No

186

Other abnormality

yes no

187

Specify other abnormality:188

Was the disease status assessed by clinical / hematologic assessment?

yes no

189

Date assessed:190 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

191

Disease Status at the Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 192 - 193

What was the disease status?192

Complete
remission (CR)

­ no lymphadenopathy; no organomegaly; neutrophils ≥ 1.5 x 109/L; platelets > 100 x 109/L; hemoglobin > 11.0 g/dL; lymphocytes < 4 x 109/L; bone
marrow < 30% lymphocytes; absence of constitutional symptoms

Partial

remission
(PR)

­ ≥ 50% decrease in peripheral blood lymphocyte count from pretreatment value; ≥ 50% reduction in lymphadenopathy if present pretreatment; ≥ 50% reduction
in liver and spleen size if enlarged pretreatment; one or more of the following: neutrophils ≥ 1.5 x 109/L or 50% improvement over baseline, platelets > 100 x
109/L or 50% improvement over baseline, hemoglobin > 11.0 g/dL or 50% improvement over baseline

Stable disease (SD) - no change; not complete remission, partial remission, nor progressive disease

Progressive
disease
(Prog)

­ one or more of the following: ≥ 50% increase in the sum of the products of ≥ 2 lymph nodes (≥ 1 node must be ≥ 2 cm) or new nodes; ≥ 50% increase in
liver or spleen size, or new hepatomegaly or splenomegaly; ≥ 50% increase in absolute lymphocyte count to ≥ 5 x 109/L; transformation to a more aggressive
histology

Untreated - no chemotherapy given in the 6 months prior to HCT

Not assessed

Date assessed:193 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

If this is a report of a second or subsequent transplant or cellular therapy for the same disease subtype and this baseline disease insert has not been completed for the previous
transplant or cellular therapy (e.g. patient was on TED track for the prior HCT, prior HCT was autologous with no consent, prior cellular therapy was not reported to the CIBMTR),
begin the form at question one.

If this is a report of a second or subsequent transplant or cellular therapy for a different disease, begin the form at question one.

Autoimmune disorder(s) at diagnosis:

Specify site(s) of disease:

Immunophenotype: (may be determined at any time after diagnosis)

Specify cytogenetic abnormalities identified at diagnosis:

Trisomy

Translocation

Deletion

Other

Specify site(s) of radiation therapy:

Specify site(s) of involvement:

Specify cytogenetic abnormalities detected at last evaluation prior to the start of the preparative regimen / infusion:

Trisomy

Translocation

Deletion

Other

Center: CRID: 

Form 2013 R3.0: Chronic Lymphocytic Leukemia (CLL) Pre-Infusion Data

CIBMTR Form 2013 revision 3.0 last updated Wednesday, November 16, 2016
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 5 / 8



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 21

What was the date of diagnosis?1 __ __ __ __ - __ __- __ __

Was documentation submitted to the CIBMTR? (e.g. pathology report used for diagnosis)

Yes No

2

Did a histologic transformation occur at any time after CLL diagnosis?

yes no

3

Date of transformation:4 __ __ __ __ - __ __- __ __

Specify the disease classification after transformation5

Diffuse large B-cell lymphoma (Richter syndrome) Also complete CIBMTR form 2018 - LYM

Other disease classification

Specify other disease classification:6

Was documentation submitted to the CIBMTR? (e.g. pathology report at transformation)

Yes No

7

Immune hemolytic anemia

Yes No Unknown

8

Immune thrombocytopenia

Yes No Unknown

9

Other

Yes No Unknown

10

Specify other autoimmune disorder:11

Rai stage (at diagnosis)

Known Unknown

12

What was the Rai stage? (at diagnosis)13

Stage 0 - Low risk - lymphocytosis (> 15,000 x 109/L) in blood or bone marrow only without lymphadenopathy, hepatosplenomegaly, anemia or thrombocytopenia

Stage I - Intermediate risk - lymphocytosis plus enlarged lymph nodes (lymphadenopathy) without hepatosplenomegaly, anemia or thrombocytopenia

Stage II - Intermediate risk - lymphocytosis plus enlarged liver or spleen with or without lymphadenopathy

Stage III - High risk - lymphocytosis plus anemia (Hgb < 11.0 g/dL) with or without enlarged liver, spleen, or lymph nodes

Stage IV - High risk - lymphocytosis plus thrombocytopenia (platelet count < 100 x 109/L) with or without anemia or enlarged liver, spleen, or lymph nodes

Binet stage (at diagnosis)

Known Unknown

14

What was the Binet stage? (at diagnosis) (Five lymphoid bearing areas are possible: axillary, cervical, inguino-femoral, liver, and spleen.)15

Stage A - two or fewer lymphoid bearing areas enlarged, without anemia or thrombocytopenia

Stage B - three or more lymphoid bearing areas enlarged, without anemia or thrombocytopenia

Stage C - presence of anemia (Hgb < 10.0 g/dL) or thrombocytopenia (platelet count < 100 x 109/L)

Were systemic symptoms (B symptoms) present? (unexplained fever > 38° C; or night sweats; unexplained weight loss > 10% of body weight in six months before diagnosis)

yes no Unknown

16

Was extranodal disease present?

Yes No

17

Central nervous system (CNS)

Yes No

18

Lung

yes no

19

Other site

yes no

20

Specify other site:21

Laboratory Studies at Diagnosis Questions: 22 - 73

WBC

Known Unknown

22

23 x 109/L (x 103/mm3)

x 106/L

Hemoglobin (untransfused)

Known Unknown

24

25 g/dL g/L mmol/L

Platelets (untransfused)

Known Unknown

26

27 x 109/L (x 103/mm3)

x 106/L

Lymphocytes

Known Unknown

28

29 %

Prolymphocytes

Known Unknown

30

31 %

LDH

Known Unknown

32

33 U/L µkat/L

Upper limit of normal for LDH:34 U/L µkat/L

Serum β2 microglobulin

Known Unknown

35

36 μg/dL mg/L nmol/L

Upper limit of normal for serum ß2 microglobulin:37 μg/dL mg/L nmol/L

Lymphocytes in bone marrow

Known Unknown

38

39 %

Leukemia cell type (may be determined at any time after diagnosis)

B-cell T-cell Unknown

40

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

41

Date sample collected:42 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

43

Specify method used44

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:45

NOTCH 1 mutation

Positive Negative Not done

46

P53 mutation

Positive Negative Not done

47

SF3B1 mutation

Positive Negative Not done

48

Other molecular marker

Positive Negative Not Done

49

Specify other molecular marker:50

Was documentation submitted to the CIBMTR?

Yes No

51

Was flow cytometry (immunophenotyping) performed?

yes no Unknown

52

CD5+

Positive Negative Not Done

53

CD19+

Positive Negative Not Done

54

CD20+

Positive Negative Not Done

55

CD23+

Positive Negative Not Done

56

CD38+

Positive Negative Not done

57

Specify percent positivity

≥30% positivity <30% positivity

58

SIg

Positive Negative Not done

59

ZAP-70 - mutated

Positive Negative Not done

60

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

61

Results of tests62

Abnormalities identified

No evaluable metaphases

No abnormalities

+12

Yes No

63

t(11;14)

yes no

64

Any other translocation of 14

Yes No

65

del(11q) / 11q–

yes no

66

del(13q) / 13q-

yes no

67

del (17p) / 17p-

yes no

68

Chromosome 6 abnormalities

Yes No

69

Chromosome 8 abnormalities

Yes No

70

Other abnormality

yes no

71

Specify other abnormality:72

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

73

Pre-HCT or Pre-Infusion Therapy Questions: 74 - 148

Was therapy given?

yes no Unknown

74

Line of Therapy (1) Questions: 75 - 148

Systemic therapy

yes no

75

Date therapy started

Known Unknown

76

Date started:77 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

78

Date stopped:79 __ __ __ __ - __ __- __ __

Number of cycles

Known Unknown

80

Number of cycles:81

Alemtuzumab (Campath)

yes no

82

Bendamustine

yes no

83

Chlorambucil (Leukeran)

yes no

84

Cladribine (2-CdA, Leustatin)

yes no

85

Corticosteroids

yes no

86

Cyclophosphamide (Cytoxan)

yes no

87

Cytarabine (Ara-C)

yes no

88

Doxorubicin (Adriamycin)

yes no

89

Etoposide (VP-16, VePesid)

yes no

90

Fludarabine (Fludara)

yes no

91

Gemcitabine (Gemzar)

yes no

92

Ibrutinib (Imbruvica)

Yes No

93

Idelalisib (Zydelig)

Yes No

94

Ifosfamide (Ifex)

yes no

95

Lenalidomide (Revlimid)

yes no

96

Nelarabine

Yes No

97

Nitrogen mustard (mustine)

yes no

98

Obinutuzumab

Yes No

99

Oblimersen

Yes No

100

Ofatumumab (Arzerra, HuMAX-CD20)

yes no

101

Pentostatin (Nipent)

yes no

102

Rituximab (anti-CD20, Rituxan)

yes no

103

Venetoclax

Yes No

104

Vincristine (VCR, Oncovin)

yes no

105

Other systemic therapy

yes no

106

Specify other systemic therapy:107

Was this line of therapy given for stem cell mobilization (priming)?

yes no

108

Radiation therapy

yes no

109

Date therapy started

Known Unknown

110

Date started:111 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

112

Date stopped:113 __ __ __ __ - __ __- __ __

Mediastinum

Yes No

114

Other site

yes no

115

Specify other site:116

Surgery

yes no

117

Date of surgery:118 __ __ __ __ - __ __- __ __

Splenectomy

yes no

119

Other site

yes no

120

Specify other site:121

Best response to line of therapy122

Complete
remission (CR)

­ no lymphadenopathy; no organomegaly; neutrophils ≥ 1.5 x 109/L; platelets > 100 x 109/L; hemoglobin > 11.0 g/dL; lymphocytes < 4 x 109/L;
bone marrow < 30% lymphocytes; absence of constitutional symptoms

Partial
remission
(PR)

- ≥ 50% decrease in peripheral blood lymphocyte count from pretreatment value; ≥ 50% reduction in lymphadenopathy if present pretreatment; ≥ 50%
reduction in liver and spleen size if enlarged pretreatment; one or more of the following: neutrophils ≥ 1.5 x 109/L or 50% improvement over baseline,
platelets > 100 x 109/L or 50% improvement over baseline, hemoglobin > 11.0 g/dL or 50% improvement over baseline

Stable disease (SD) - no change; not complete remission, partial remission, nor progressive disease

Progressive
disease
(Prog)

­ one or more of the following: ≥ 50% increase in the sum of the products of ≥ 2 lymph nodes (≥ 1 node must be ≥ 2 cm) or new nodes; ≥ 50%
increase in liver or spleen size, or new hepatomegaly or splenomegaly; ≥ 50% increase in absolute lymphocyte count to ≥ 5 x 109/L; transformation to
a more aggressive histology

Not assessed

Unknown

Date assessed:123 __ __ __ __ - __ __- __ __

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

124

Date sample collected:125 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

126

Specify method used127

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:128

NOTCH 1 mutation

Positive Negative Not done

129

P53 mutation

Positive Negative Not done

130

SF3B1 mutation

Positive Negative Not done

131

Other molecular marker

Positive Negative Not Done

132

Specify other molecular marker:133

Was the disease status assessed via flow cytometry? (minimum 4-color flow) (immunophenotyping)

yes no

134

Date sample collected:135 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

136

Was the disease status assessed by cytogenetic testing (karyotyping or FISH)?

yes no

137

Was the disease status assessed via FISH?

yes no

138

Date sample collected:139 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

140

Was the disease status assessed via karyotyping?

Yes No

141

Date sample collected:142 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

143

Was the disease status assessed by clinical / hematologic assessment?

yes no

144

Date assessed:145 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

146

Did disease relapse/progress following this line of therapy?

yes no

147

Date of relapse/progression:148 __ __ __ __ - __ __- __ __

Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 149 - 191

Did the recipient have known nodal involvement?

yes no

149

Specify the size of the largest nodal mass:150 cm x cm

Was extranodal disease present?

Yes No

151

Central nervous system (CNS)

Yes No

152

Lung

yes no

153

Other site

yes no

154

Specify other site:155

Prolymphocytes

Known Unknown

156

157 %

Serum β2 microglobulin

Known Unknown

158

159 μg/dL mg/L nmol/L

Upper limit of normal for serum ß2 microglobulin:160 μg/dL mg/L nmol/L

Lymphocytes in bone marrow

Known Unknown

161

162 %

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

163

Date sample collected:164 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

165

Specify method used166

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:167

NOTCH 1 mutation

Positive Negative Not done

168

P53 mutation

Positive Negative Not done

169

SF3B1 mutation

Positive Negative Not done

170

Other molecular marker

Positive Negative Not Done

171

Specify other molecular marker:172

Was documentation submitted to the CIBMTR?

Yes No

173

Was the disease status assessed via flow cytometry? (minimum 4-color flow) (immunophenotyping)

yes no

174

Date sample collected:175 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

176

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

177

Results of tests178

Abnormalities identified

No evaluable metaphases

No abnormalities

+12

Yes No

179

t(11;14)

yes no

180

Any other translocation of 14

Yes No

181

del(11q) / 11q–

yes no

182

del(13q) / 13q-

yes no

183

del (17p) / 17p-

yes no

184

Chromosome 6 abnormalities

Yes No

185

Chromosome 8 abnormalities

Yes No

186

Other abnormality

yes no

187

Specify other abnormality:188

Was the disease status assessed by clinical / hematologic assessment?

yes no

189

Date assessed:190 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

191

Disease Status at the Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 192 - 193

What was the disease status?192

Complete
remission (CR)

­ no lymphadenopathy; no organomegaly; neutrophils ≥ 1.5 x 109/L; platelets > 100 x 109/L; hemoglobin > 11.0 g/dL; lymphocytes < 4 x 109/L; bone
marrow < 30% lymphocytes; absence of constitutional symptoms

Partial
remission
(PR)

­ ≥ 50% decrease in peripheral blood lymphocyte count from pretreatment value; ≥ 50% reduction in lymphadenopathy if present pretreatment; ≥ 50% reduction
in liver and spleen size if enlarged pretreatment; one or more of the following: neutrophils ≥ 1.5 x 109/L or 50% improvement over baseline, platelets > 100 x
109/L or 50% improvement over baseline, hemoglobin > 11.0 g/dL or 50% improvement over baseline

Stable disease (SD) - no change; not complete remission, partial remission, nor progressive disease

Progressive
disease
(Prog)

­ one or more of the following: ≥ 50% increase in the sum of the products of ≥ 2 lymph nodes (≥ 1 node must be ≥ 2 cm) or new nodes; ≥ 50% increase in
liver or spleen size, or new hepatomegaly or splenomegaly; ≥ 50% increase in absolute lymphocyte count to ≥ 5 x 109/L; transformation to a more aggressive
histology

Untreated - no chemotherapy given in the 6 months prior to HCT

Not assessed

Date assessed:193 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

If this is a report of a second or subsequent transplant or cellular therapy for the same disease subtype and this baseline disease insert has not been completed for the previous
transplant or cellular therapy (e.g. patient was on TED track for the prior HCT, prior HCT was autologous with no consent, prior cellular therapy was not reported to the CIBMTR),
begin the form at question one.

If this is a report of a second or subsequent transplant or cellular therapy for a different disease, begin the form at question one.

Autoimmune disorder(s) at diagnosis:

Specify site(s) of disease:

Immunophenotype: (may be determined at any time after diagnosis)

Specify cytogenetic abnormalities identified at diagnosis:

Trisomy

Translocation

Deletion

Other

Specify site(s) of radiation therapy:

Specify site(s) of involvement:

Specify cytogenetic abnormalities detected at last evaluation prior to the start of the preparative regimen / infusion:

Trisomy

Translocation

Deletion

Other

Center: CRID: 

Form 2013 R3.0: Chronic Lymphocytic Leukemia (CLL) Pre-Infusion Data

CIBMTR Form 2013 revision 3.0 last updated Wednesday, November 16, 2016
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 6 / 8



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 21

What was the date of diagnosis?1 __ __ __ __ - __ __- __ __

Was documentation submitted to the CIBMTR? (e.g. pathology report used for diagnosis)

Yes No

2

Did a histologic transformation occur at any time after CLL diagnosis?

yes no

3

Date of transformation:4 __ __ __ __ - __ __- __ __

Specify the disease classification after transformation5

Diffuse large B-cell lymphoma (Richter syndrome) Also complete CIBMTR form 2018 - LYM

Other disease classification

Specify other disease classification:6

Was documentation submitted to the CIBMTR? (e.g. pathology report at transformation)

Yes No

7

Immune hemolytic anemia

Yes No Unknown

8

Immune thrombocytopenia

Yes No Unknown

9

Other

Yes No Unknown

10

Specify other autoimmune disorder:11

Rai stage (at diagnosis)

Known Unknown

12

What was the Rai stage? (at diagnosis)13

Stage 0 - Low risk - lymphocytosis (> 15,000 x 109/L) in blood or bone marrow only without lymphadenopathy, hepatosplenomegaly, anemia or thrombocytopenia

Stage I - Intermediate risk - lymphocytosis plus enlarged lymph nodes (lymphadenopathy) without hepatosplenomegaly, anemia or thrombocytopenia

Stage II - Intermediate risk - lymphocytosis plus enlarged liver or spleen with or without lymphadenopathy

Stage III - High risk - lymphocytosis plus anemia (Hgb < 11.0 g/dL) with or without enlarged liver, spleen, or lymph nodes

Stage IV - High risk - lymphocytosis plus thrombocytopenia (platelet count < 100 x 109/L) with or without anemia or enlarged liver, spleen, or lymph nodes

Binet stage (at diagnosis)

Known Unknown

14

What was the Binet stage? (at diagnosis) (Five lymphoid bearing areas are possible: axillary, cervical, inguino-femoral, liver, and spleen.)15

Stage A - two or fewer lymphoid bearing areas enlarged, without anemia or thrombocytopenia

Stage B - three or more lymphoid bearing areas enlarged, without anemia or thrombocytopenia

Stage C - presence of anemia (Hgb < 10.0 g/dL) or thrombocytopenia (platelet count < 100 x 109/L)

Were systemic symptoms (B symptoms) present? (unexplained fever > 38° C; or night sweats; unexplained weight loss > 10% of body weight in six months before diagnosis)

yes no Unknown

16

Was extranodal disease present?

Yes No

17

Central nervous system (CNS)

Yes No

18

Lung

yes no

19

Other site

yes no

20

Specify other site:21

Laboratory Studies at Diagnosis Questions: 22 - 73

WBC

Known Unknown

22

23 x 109/L (x 103/mm3)

x 106/L

Hemoglobin (untransfused)

Known Unknown

24

25 g/dL g/L mmol/L

Platelets (untransfused)

Known Unknown

26

27 x 109/L (x 103/mm3)

x 106/L

Lymphocytes

Known Unknown

28

29 %

Prolymphocytes

Known Unknown

30

31 %

LDH

Known Unknown

32

33 U/L µkat/L

Upper limit of normal for LDH:34 U/L µkat/L

Serum β2 microglobulin

Known Unknown

35

36 μg/dL mg/L nmol/L

Upper limit of normal for serum ß2 microglobulin:37 μg/dL mg/L nmol/L

Lymphocytes in bone marrow

Known Unknown

38

39 %

Leukemia cell type (may be determined at any time after diagnosis)

B-cell T-cell Unknown

40

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

41

Date sample collected:42 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

43

Specify method used44

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:45

NOTCH 1 mutation

Positive Negative Not done

46

P53 mutation

Positive Negative Not done

47

SF3B1 mutation

Positive Negative Not done

48

Other molecular marker

Positive Negative Not Done

49

Specify other molecular marker:50

Was documentation submitted to the CIBMTR?

Yes No

51

Was flow cytometry (immunophenotyping) performed?

yes no Unknown

52

CD5+

Positive Negative Not Done

53

CD19+

Positive Negative Not Done

54

CD20+

Positive Negative Not Done

55

CD23+

Positive Negative Not Done

56

CD38+

Positive Negative Not done

57

Specify percent positivity

≥30% positivity <30% positivity

58

SIg

Positive Negative Not done

59

ZAP-70 - mutated

Positive Negative Not done

60

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

61

Results of tests62

Abnormalities identified

No evaluable metaphases

No abnormalities

+12

Yes No

63

t(11;14)

yes no

64

Any other translocation of 14

Yes No

65

del(11q) / 11q–

yes no

66

del(13q) / 13q-

yes no

67

del (17p) / 17p-

yes no

68

Chromosome 6 abnormalities

Yes No

69

Chromosome 8 abnormalities

Yes No

70

Other abnormality

yes no

71

Specify other abnormality:72

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

73

Pre-HCT or Pre-Infusion Therapy Questions: 74 - 148

Was therapy given?

yes no Unknown

74

Line of Therapy (1) Questions: 75 - 148

Systemic therapy

yes no

75

Date therapy started

Known Unknown

76

Date started:77 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

78

Date stopped:79 __ __ __ __ - __ __- __ __

Number of cycles

Known Unknown

80

Number of cycles:81

Alemtuzumab (Campath)

yes no

82

Bendamustine

yes no

83

Chlorambucil (Leukeran)

yes no

84

Cladribine (2-CdA, Leustatin)

yes no

85

Corticosteroids

yes no

86

Cyclophosphamide (Cytoxan)

yes no

87

Cytarabine (Ara-C)

yes no

88

Doxorubicin (Adriamycin)

yes no

89

Etoposide (VP-16, VePesid)

yes no

90

Fludarabine (Fludara)

yes no

91

Gemcitabine (Gemzar)

yes no

92

Ibrutinib (Imbruvica)

Yes No

93

Idelalisib (Zydelig)

Yes No

94

Ifosfamide (Ifex)

yes no

95

Lenalidomide (Revlimid)

yes no

96

Nelarabine

Yes No

97

Nitrogen mustard (mustine)

yes no

98

Obinutuzumab

Yes No

99

Oblimersen

Yes No

100

Ofatumumab (Arzerra, HuMAX-CD20)

yes no

101

Pentostatin (Nipent)

yes no

102

Rituximab (anti-CD20, Rituxan)

yes no

103

Venetoclax

Yes No

104

Vincristine (VCR, Oncovin)

yes no

105

Other systemic therapy

yes no

106

Specify other systemic therapy:107

Was this line of therapy given for stem cell mobilization (priming)?

yes no

108

Radiation therapy

yes no

109

Date therapy started

Known Unknown

110

Date started:111 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

112

Date stopped:113 __ __ __ __ - __ __- __ __

Mediastinum

Yes No

114

Other site

yes no

115

Specify other site:116

Surgery

yes no

117

Date of surgery:118 __ __ __ __ - __ __- __ __

Splenectomy

yes no

119

Other site

yes no

120

Specify other site:121

Best response to line of therapy122

Complete
remission (CR)

­ no lymphadenopathy; no organomegaly; neutrophils ≥ 1.5 x 109/L; platelets > 100 x 109/L; hemoglobin > 11.0 g/dL; lymphocytes < 4 x 109/L;
bone marrow < 30% lymphocytes; absence of constitutional symptoms

Partial
remission
(PR)

- ≥ 50% decrease in peripheral blood lymphocyte count from pretreatment value; ≥ 50% reduction in lymphadenopathy if present pretreatment; ≥ 50%
reduction in liver and spleen size if enlarged pretreatment; one or more of the following: neutrophils ≥ 1.5 x 109/L or 50% improvement over baseline,
platelets > 100 x 109/L or 50% improvement over baseline, hemoglobin > 11.0 g/dL or 50% improvement over baseline

Stable disease (SD) - no change; not complete remission, partial remission, nor progressive disease

Progressive
disease
(Prog)

­ one or more of the following: ≥ 50% increase in the sum of the products of ≥ 2 lymph nodes (≥ 1 node must be ≥ 2 cm) or new nodes; ≥ 50%
increase in liver or spleen size, or new hepatomegaly or splenomegaly; ≥ 50% increase in absolute lymphocyte count to ≥ 5 x 109/L; transformation to
a more aggressive histology

Not assessed

Unknown

Date assessed:123 __ __ __ __ - __ __- __ __

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

124

Date sample collected:125 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

126

Specify method used127

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:128

NOTCH 1 mutation

Positive Negative Not done

129

P53 mutation

Positive Negative Not done

130

SF3B1 mutation

Positive Negative Not done

131

Other molecular marker

Positive Negative Not Done

132

Specify other molecular marker:133

Was the disease status assessed via flow cytometry? (minimum 4-color flow) (immunophenotyping)

yes no

134

Date sample collected:135 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

136

Was the disease status assessed by cytogenetic testing (karyotyping or FISH)?

yes no

137

Was the disease status assessed via FISH?

yes no

138

Date sample collected:139 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

140

Was the disease status assessed via karyotyping?

Yes No

141

Date sample collected:142 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

143

Was the disease status assessed by clinical / hematologic assessment?

yes no

144

Date assessed:145 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

146

Did disease relapse/progress following this line of therapy?

yes no

147

Date of relapse/progression:148 __ __ __ __ - __ __- __ __

Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 149 - 191

Did the recipient have known nodal involvement?

yes no

149

Specify the size of the largest nodal mass:150 cm x cm

Was extranodal disease present?

Yes No

151

Central nervous system (CNS)

Yes No

152

Lung

yes no

153

Other site

yes no

154

Specify other site:155

Prolymphocytes

Known Unknown

156

157 %

Serum β2 microglobulin

Known Unknown

158

159 μg/dL mg/L nmol/L

Upper limit of normal for serum ß2 microglobulin:160 μg/dL mg/L nmol/L

Lymphocytes in bone marrow

Known Unknown

161

162 %

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

163

Date sample collected:164 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

165

Specify method used166

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:167

NOTCH 1 mutation

Positive Negative Not done

168

P53 mutation

Positive Negative Not done

169

SF3B1 mutation

Positive Negative Not done

170

Other molecular marker

Positive Negative Not Done

171

Specify other molecular marker:172

Was documentation submitted to the CIBMTR?

Yes No

173

Was the disease status assessed via flow cytometry? (minimum 4-color flow) (immunophenotyping)

yes no

174

Date sample collected:175 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

176

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

177

Results of tests178

Abnormalities identified

No evaluable metaphases

No abnormalities

+12

Yes No

179

t(11;14)

yes no

180

Any other translocation of 14

Yes No

181

del(11q) / 11q–

yes no

182

del(13q) / 13q-

yes no

183

del (17p) / 17p-

yes no

184

Chromosome 6 abnormalities

Yes No

185

Chromosome 8 abnormalities

Yes No

186

Other abnormality

yes no

187

Specify other abnormality:188

Was the disease status assessed by clinical / hematologic assessment?

yes no

189

Date assessed:190 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

191

Disease Status at the Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 192 - 193

What was the disease status?192

Complete
remission (CR)

­ no lymphadenopathy; no organomegaly; neutrophils ≥ 1.5 x 109/L; platelets > 100 x 109/L; hemoglobin > 11.0 g/dL; lymphocytes < 4 x 109/L; bone
marrow < 30% lymphocytes; absence of constitutional symptoms

Partial
remission
(PR)

­ ≥ 50% decrease in peripheral blood lymphocyte count from pretreatment value; ≥ 50% reduction in lymphadenopathy if present pretreatment; ≥ 50% reduction
in liver and spleen size if enlarged pretreatment; one or more of the following: neutrophils ≥ 1.5 x 109/L or 50% improvement over baseline, platelets > 100 x
109/L or 50% improvement over baseline, hemoglobin > 11.0 g/dL or 50% improvement over baseline

Stable disease (SD) - no change; not complete remission, partial remission, nor progressive disease

Progressive
disease
(Prog)

­ one or more of the following: ≥ 50% increase in the sum of the products of ≥ 2 lymph nodes (≥ 1 node must be ≥ 2 cm) or new nodes; ≥ 50% increase in
liver or spleen size, or new hepatomegaly or splenomegaly; ≥ 50% increase in absolute lymphocyte count to ≥ 5 x 109/L; transformation to a more aggressive
histology

Untreated - no chemotherapy given in the 6 months prior to HCT

Not assessed

Date assessed:193 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

If this is a report of a second or subsequent transplant or cellular therapy for the same disease subtype and this baseline disease insert has not been completed for the previous
transplant or cellular therapy (e.g. patient was on TED track for the prior HCT, prior HCT was autologous with no consent, prior cellular therapy was not reported to the CIBMTR),
begin the form at question one.

If this is a report of a second or subsequent transplant or cellular therapy for a different disease, begin the form at question one.

Autoimmune disorder(s) at diagnosis:

Specify site(s) of disease:

Immunophenotype: (may be determined at any time after diagnosis)

Specify cytogenetic abnormalities identified at diagnosis:

Trisomy

Translocation

Deletion

Other

Specify site(s) of radiation therapy:

Specify site(s) of involvement:

Specify cytogenetic abnormalities detected at last evaluation prior to the start of the preparative regimen / infusion:

Trisomy

Translocation

Deletion

Other

Center: CRID: 

Form 2013 R3.0: Chronic Lymphocytic Leukemia (CLL) Pre-Infusion Data

CIBMTR Form 2013 revision 3.0 last updated Wednesday, November 16, 2016
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 7 / 8



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant or cellular therapy for the same disease?

Yes No

Disease Assessment at Diagnosis Questions: 1 - 21

What was the date of diagnosis?1 __ __ __ __ - __ __- __ __

Was documentation submitted to the CIBMTR? (e.g. pathology report used for diagnosis)

Yes No

2

Did a histologic transformation occur at any time after CLL diagnosis?

yes no

3

Date of transformation:4 __ __ __ __ - __ __- __ __

Specify the disease classification after transformation5

Diffuse large B-cell lymphoma (Richter syndrome) Also complete CIBMTR form 2018 - LYM

Other disease classification

Specify other disease classification:6

Was documentation submitted to the CIBMTR? (e.g. pathology report at transformation)

Yes No

7

Immune hemolytic anemia

Yes No Unknown

8

Immune thrombocytopenia

Yes No Unknown

9

Other

Yes No Unknown

10

Specify other autoimmune disorder:11

Rai stage (at diagnosis)

Known Unknown

12

What was the Rai stage? (at diagnosis)13

Stage 0 - Low risk - lymphocytosis (> 15,000 x 109/L) in blood or bone marrow only without lymphadenopathy, hepatosplenomegaly, anemia or thrombocytopenia

Stage I - Intermediate risk - lymphocytosis plus enlarged lymph nodes (lymphadenopathy) without hepatosplenomegaly, anemia or thrombocytopenia

Stage II - Intermediate risk - lymphocytosis plus enlarged liver or spleen with or without lymphadenopathy

Stage III - High risk - lymphocytosis plus anemia (Hgb < 11.0 g/dL) with or without enlarged liver, spleen, or lymph nodes

Stage IV - High risk - lymphocytosis plus thrombocytopenia (platelet count < 100 x 109/L) with or without anemia or enlarged liver, spleen, or lymph nodes

Binet stage (at diagnosis)

Known Unknown

14

What was the Binet stage? (at diagnosis) (Five lymphoid bearing areas are possible: axillary, cervical, inguino-femoral, liver, and spleen.)15

Stage A - two or fewer lymphoid bearing areas enlarged, without anemia or thrombocytopenia

Stage B - three or more lymphoid bearing areas enlarged, without anemia or thrombocytopenia

Stage C - presence of anemia (Hgb < 10.0 g/dL) or thrombocytopenia (platelet count < 100 x 109/L)

Were systemic symptoms (B symptoms) present? (unexplained fever > 38° C; or night sweats; unexplained weight loss > 10% of body weight in six months before diagnosis)

yes no Unknown

16

Was extranodal disease present?

Yes No

17

Central nervous system (CNS)

Yes No

18

Lung

yes no

19

Other site

yes no

20

Specify other site:21

Laboratory Studies at Diagnosis Questions: 22 - 73

WBC

Known Unknown

22

23 x 109/L (x 103/mm3)

x 106/L

Hemoglobin (untransfused)

Known Unknown

24

25 g/dL g/L mmol/L

Platelets (untransfused)

Known Unknown

26

27 x 109/L (x 103/mm3)

x 106/L

Lymphocytes

Known Unknown

28

29 %

Prolymphocytes

Known Unknown

30

31 %

LDH

Known Unknown

32

33 U/L µkat/L

Upper limit of normal for LDH:34 U/L µkat/L

Serum β2 microglobulin

Known Unknown

35

36 μg/dL mg/L nmol/L

Upper limit of normal for serum ß2 microglobulin:37 μg/dL mg/L nmol/L

Lymphocytes in bone marrow

Known Unknown

38

39 %

Leukemia cell type (may be determined at any time after diagnosis)

B-cell T-cell Unknown

40

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

41

Date sample collected:42 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

43

Specify method used44

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:45

NOTCH 1 mutation

Positive Negative Not done

46

P53 mutation

Positive Negative Not done

47

SF3B1 mutation

Positive Negative Not done

48

Other molecular marker

Positive Negative Not Done

49

Specify other molecular marker:50

Was documentation submitted to the CIBMTR?

Yes No

51

Was flow cytometry (immunophenotyping) performed?

yes no Unknown

52

CD5+

Positive Negative Not Done

53

CD19+

Positive Negative Not Done

54

CD20+

Positive Negative Not Done

55

CD23+

Positive Negative Not Done

56

CD38+

Positive Negative Not done

57

Specify percent positivity

≥30% positivity <30% positivity

58

SIg

Positive Negative Not done

59

ZAP-70 - mutated

Positive Negative Not done

60

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

61

Results of tests62

Abnormalities identified

No evaluable metaphases

No abnormalities

+12

Yes No

63

t(11;14)

yes no

64

Any other translocation of 14

Yes No

65

del(11q) / 11q–

yes no

66

del(13q) / 13q-

yes no

67

del (17p) / 17p-

yes no

68

Chromosome 6 abnormalities

Yes No

69

Chromosome 8 abnormalities

Yes No

70

Other abnormality

yes no

71

Specify other abnormality:72

Was documentation submitted to the CIBMTR? (e.g. cytogenetic or FISH report)

Yes No

73

Pre-HCT or Pre-Infusion Therapy Questions: 74 - 148

Was therapy given?

yes no Unknown

74

Line of Therapy (1) Questions: 75 - 148

Systemic therapy

yes no

75

Date therapy started

Known Unknown

76

Date started:77 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

78

Date stopped:79 __ __ __ __ - __ __- __ __

Number of cycles

Known Unknown

80

Number of cycles:81

Alemtuzumab (Campath)

yes no

82

Bendamustine

yes no

83

Chlorambucil (Leukeran)

yes no

84

Cladribine (2-CdA, Leustatin)

yes no

85

Corticosteroids

yes no

86

Cyclophosphamide (Cytoxan)

yes no

87

Cytarabine (Ara-C)

yes no

88

Doxorubicin (Adriamycin)

yes no

89

Etoposide (VP-16, VePesid)

yes no

90

Fludarabine (Fludara)

yes no

91

Gemcitabine (Gemzar)

yes no

92

Ibrutinib (Imbruvica)

Yes No

93

Idelalisib (Zydelig)

Yes No

94

Ifosfamide (Ifex)

yes no

95

Lenalidomide (Revlimid)

yes no

96

Nelarabine

Yes No

97

Nitrogen mustard (mustine)

yes no

98

Obinutuzumab

Yes No

99

Oblimersen

Yes No

100

Ofatumumab (Arzerra, HuMAX-CD20)

yes no

101

Pentostatin (Nipent)

yes no

102

Rituximab (anti-CD20, Rituxan)

yes no

103

Venetoclax

Yes No

104

Vincristine (VCR, Oncovin)

yes no

105

Other systemic therapy

yes no

106

Specify other systemic therapy:107

Was this line of therapy given for stem cell mobilization (priming)?

yes no

108

Radiation therapy

yes no

109

Date therapy started

Known Unknown

110

Date started:111 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

112

Date stopped:113 __ __ __ __ - __ __- __ __

Mediastinum

Yes No

114

Other site

yes no

115

Specify other site:116

Surgery

yes no

117

Date of surgery:118 __ __ __ __ - __ __- __ __

Splenectomy

yes no

119

Other site

yes no

120

Specify other site:121

Best response to line of therapy122

Complete
remission (CR)

­ no lymphadenopathy; no organomegaly; neutrophils ≥ 1.5 x 109/L; platelets > 100 x 109/L; hemoglobin > 11.0 g/dL; lymphocytes < 4 x 109/L;
bone marrow < 30% lymphocytes; absence of constitutional symptoms

Partial
remission
(PR)

- ≥ 50% decrease in peripheral blood lymphocyte count from pretreatment value; ≥ 50% reduction in lymphadenopathy if present pretreatment; ≥ 50%
reduction in liver and spleen size if enlarged pretreatment; one or more of the following: neutrophils ≥ 1.5 x 109/L or 50% improvement over baseline,
platelets > 100 x 109/L or 50% improvement over baseline, hemoglobin > 11.0 g/dL or 50% improvement over baseline

Stable disease (SD) - no change; not complete remission, partial remission, nor progressive disease

Progressive
disease
(Prog)

­ one or more of the following: ≥ 50% increase in the sum of the products of ≥ 2 lymph nodes (≥ 1 node must be ≥ 2 cm) or new nodes; ≥ 50%
increase in liver or spleen size, or new hepatomegaly or splenomegaly; ≥ 50% increase in absolute lymphocyte count to ≥ 5 x 109/L; transformation to
a more aggressive histology

Not assessed

Unknown

Date assessed:123 __ __ __ __ - __ __- __ __

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

124

Date sample collected:125 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

126

Specify method used127

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:128

NOTCH 1 mutation

Positive Negative Not done

129

P53 mutation

Positive Negative Not done

130

SF3B1 mutation

Positive Negative Not done

131

Other molecular marker

Positive Negative Not Done

132

Specify other molecular marker:133

Was the disease status assessed via flow cytometry? (minimum 4-color flow) (immunophenotyping)

yes no

134

Date sample collected:135 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

136

Was the disease status assessed by cytogenetic testing (karyotyping or FISH)?

yes no

137

Was the disease status assessed via FISH?

yes no

138

Date sample collected:139 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

140

Was the disease status assessed via karyotyping?

Yes No

141

Date sample collected:142 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

143

Was the disease status assessed by clinical / hematologic assessment?

yes no

144

Date assessed:145 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

146

Did disease relapse/progress following this line of therapy?

yes no

147

Date of relapse/progression:148 __ __ __ __ - __ __- __ __

Disease Assessment at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 149 - 191

Did the recipient have known nodal involvement?

yes no

149

Specify the size of the largest nodal mass:150 cm x cm

Was extranodal disease present?

Yes No

151

Central nervous system (CNS)

Yes No

152

Lung

yes no

153

Other site

yes no

154

Specify other site:155

Prolymphocytes

Known Unknown

156

157 %

Serum β2 microglobulin

Known Unknown

158

159 μg/dL mg/L nmol/L

Upper limit of normal for serum ß2 microglobulin:160 μg/dL mg/L nmol/L

Lymphocytes in bone marrow

Known Unknown

161

162 %

Were tests for molecular markers performed (e.g. PCR)?

yes no Unknown

163

Date sample collected:164 __ __ __ __ - __ __- __ __

Immunoglobulin heavy chain variable (IGHV) mutation

Positive Negative Not done

165

Specify method used166

ASO IGHV RQ-PCR

Consensus IGHV PCR

Consensus IGHV PCR using HTS

Nested ASO IGHV PCR

Other method

Specify other method:167

NOTCH 1 mutation

Positive Negative Not done

168

P53 mutation

Positive Negative Not done

169

SF3B1 mutation

Positive Negative Not done

170

Other molecular marker

Positive Negative Not Done

171

Specify other molecular marker:172

Was documentation submitted to the CIBMTR?

Yes No

173

Was the disease status assessed via flow cytometry? (minimum 4-color flow) (immunophenotyping)

yes no

174

Date sample collected:175 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

176

Were cytogenetics tested (karyotyping or FISH)?

yes no Unknown

177

Results of tests178

Abnormalities identified

No evaluable metaphases

No abnormalities

+12

Yes No

179

t(11;14)

yes no

180

Any other translocation of 14

Yes No

181

del(11q) / 11q–

yes no

182

del(13q) / 13q-

yes no

183

del (17p) / 17p-

yes no

184

Chromosome 6 abnormalities

Yes No

185

Chromosome 8 abnormalities

Yes No

186

Other abnormality

yes no

187

Specify other abnormality:188

Was the disease status assessed by clinical / hematologic assessment?

yes no

189

Date assessed:190 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

191

Disease Status at the Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 192 - 193

What was the disease status?192

Complete
remission (CR)

­ no lymphadenopathy; no organomegaly; neutrophils ≥ 1.5 x 109/L; platelets > 100 x 109/L; hemoglobin > 11.0 g/dL; lymphocytes < 4 x 109/L; bone
marrow < 30% lymphocytes; absence of constitutional symptoms

Partial
remission
(PR)

­ ≥ 50% decrease in peripheral blood lymphocyte count from pretreatment value; ≥ 50% reduction in lymphadenopathy if present pretreatment; ≥ 50% reduction
in liver and spleen size if enlarged pretreatment; one or more of the following: neutrophils ≥ 1.5 x 109/L or 50% improvement over baseline, platelets > 100 x
109/L or 50% improvement over baseline, hemoglobin > 11.0 g/dL or 50% improvement over baseline

Stable disease (SD) - no change; not complete remission, partial remission, nor progressive disease

Progressive
disease
(Prog)

­ one or more of the following: ≥ 50% increase in the sum of the products of ≥ 2 lymph nodes (≥ 1 node must be ≥ 2 cm) or new nodes; ≥ 50% increase in
liver or spleen size, or new hepatomegaly or splenomegaly; ≥ 50% increase in absolute lymphocyte count to ≥ 5 x 109/L; transformation to a more aggressive
histology

Untreated - no chemotherapy given in the 6 months prior to HCT

Not assessed

Date assessed:193 __ __ __ __ - __ __- __ __

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

If this is a report of a second or subsequent transplant or cellular therapy for the same disease subtype and this baseline disease insert has not been completed for the previous
transplant or cellular therapy (e.g. patient was on TED track for the prior HCT, prior HCT was autologous with no consent, prior cellular therapy was not reported to the CIBMTR),
begin the form at question one.

If this is a report of a second or subsequent transplant or cellular therapy for a different disease, begin the form at question one.

Autoimmune disorder(s) at diagnosis:

Specify site(s) of disease:

Immunophenotype: (may be determined at any time after diagnosis)

Specify cytogenetic abnormalities identified at diagnosis:

Trisomy

Translocation

Deletion

Other

Specify site(s) of radiation therapy:

Specify site(s) of involvement:

Specify cytogenetic abnormalities detected at last evaluation prior to the start of the preparative regimen / infusion:

Trisomy

Translocation

Deletion

Other

Center: CRID: 

Form 2013 R3.0: Chronic Lymphocytic Leukemia (CLL) Pre-Infusion Data

CIBMTR Form 2013 revision 3.0 last updated Wednesday, November 16, 2016
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 8 / 8